A. Keith Stewart, MB, ChB
Carlson and Nelson Endowed Medical Director, Mayo Clinic Center for Individualized Medicine
Dr. Keith Stewart is a consultant in the Division of Hematology/Oncology at Mayo Clinic; and recognized as the Vasek and Anna Maria Polak Professor of Cancer Research.
Dr. Stewart received an M.B., Ch.B. degree at Aberdeen University Medical School in the United Kingdom; and an MBA degree at the University of Western Ontario.
He has more than 20 years of sustained national funding for laboratory research programs focusing on genomics and individualized treatment of multiple myeloma; and has led numerous clinical trials for multiple myeloma.
Dr. Stewart serves as Dean for Research in Arizona and is a member of the Arizona Executive Operations Team and Clinical Practice Committee.
Dr. Stewart has authored more than 250 publications and was an associate editor for Blood from 2009-2014. He has served on multiple national committees and advisory boards recently, including the National Cancer Institute Experimental Therapeutics Study Section Chair; the Medical and Scientific Advisory Board of the Leukemia & Lymphoma Society; and the Investment and Audit Committee of the American Society of Hematology.
Host, Minnesota Public Radio (MPR)
Cathy Wurzer is the host of Morning Edition on the MPR News network. She is also the co-host of Almanac, a weekly public affairs program for Minnesota's statewide public television network, the longest running program of its kind in the nation. Ms. Wurzer holds degrees in broadcast journalism and urban studies from the University of Wisconsin-River Falls.
Prior to her work with MPR News, Ms. Wurzer anchored and reported for WCCO-TV, the CBS affiliate in Minneapolis. In addition, she was a talk show host for WCCO-AM radio, a producer for KMSP-TV, and a political reporter for KSTP-AM radio.
She is the author of "Tales of the Road: Highway 61" and co author of the recently released "We Know How This Ends: Living while Dying" published by the University of Minnesota Press with Bruce Kramer, the former Dean of the College of Education at the University of St. Thomas. The book is a follow up to their award winning series of MPR News radio interviews on Bruce Kramer's life with ALS.
Ms. Wurzer was awarded multiple Emmy Awards for her work on Almanac, and is a member and past president of the Society for Professional Journalists Minnesota chapter.
Athena Aktipis, Ph.D.
Associate Professor of Psychology Department, Arizona State University
Dr. Athena Aktipis is an Assistant Professor in the Psychology Department at Arizona State University, co-Director of the Human Generosity Project, Director of Human and Social Evolution, and co-founder of the Center for Evolution and Cancer at the University of California. Dr. Aktipis completed a B.A. degree at Reed College (Psychology), a Ph.D. at University of Pennsylvania (Psychology), and post-doctoral work at University of Arizona (Ecology and Evolutionary Biology).
She is a cooperation theorist, theoretical evolutionary biologist, and cancer biologist who now works at the intersection of these fields.
Dr. Aktipis is the author of the forthcoming book from Princeton University Press "Evolution in the flesh: Cancer and the transformation of life."
C. Anthony Altar, Ph.D.
Senior Vice President, Neuroscience, AssureRx Health, Inc.
Dr. C. Anthony Altar is an early member of AssureRx Health, Inc. As Senior Vice President, Neurosciences, he is responsible for the research of pharmacogenomic products.
Before joining the Assurex Health, Inc., team, Dr. Altar directed the Alzheimer's Diagnostic Laboratory for the Blanchette Rockefeller Neuroscience Institute. Dr. Altar earned a B.S. with Honors in Psychobiology from UCLA and a Ph.D., with Honors in Psychology from UC Santa Barbara.
As a postdoctoral scientist at UC Irvine, Dr. Altar created digital imaging of receptor-drug binding in the brain and while at UC Irvine, and Ciba-Geigy, he identified the serotonin/dopamine receptor binding profile of atypical antipsychotics. At Genentech and Regeneron Pharmaceuticals, Dr. Altar pioneered research of neurotrophic factors, and was the first to discover roles for BDNF in serotonin function, pain, and depression.
As global director for neuroscience at Otsuka, Dr. Altar led the team that discovered Abilify, its likely uses in psychosis, depression and bipolar illness, and helped lead the effort in its FDA approval. His teams at Psychiatric Genomics Inc. used genomics to discover the insulin-deficiency of schizophrenia and validated drug targets for this approach. He launched the Biomarkers Consortium within the Foundation for NIH.
Dr. Altar has published 135 neuroscience and drug discovery articles in peer-reviewed journals including Science and Nature.
John Alverdy, M.D., F.A.C.
Professor of Surgery, University of Chicago
Dr. John Alverdy is the Sarah and Harold Lincoln Thompson Professor of Surgery at the University of Chicago, vice chair of the Department of Surgery, and a gastrointestinal surgeon specializing in minimally invasive surgery.
Dr. Alverdy maintains an active surgical practice while exploring the role of the intestinal microbiome, and pathobiome in surgical diseases including critical illness, and anastomotic complications.
His research interests are funded by the NIH, and include the study of intestinal bacteria in surgical complications including sepsis, and anastomotic leak.
Karen Anderson, M.D., Ph.D.
Associate Professor, Biodesign Institute, Mayo Clinic and Arizona State University
Dr. Karen Anderson holds a joint appointment as an Associate Professor at the Biodesign Institute at Arizona State University, and Mayo Clinic in Arizona. She received her B.A. in Chemistry from the University of Virginia, and her M.D. and Ph.D. in Immunology from Duke University School of Medicine. She completed her clinical training in internal medicine at the Brigham and Women's Hospital, and her Hematology and Oncology Fellowship at the Dana Farber Cancer Institute, where she remained as faculty until 2011.
Dr. Anderson’s laboratory is focused on the development of effective cancer immunotherapy, and proteome-wide immune monitoring.
Stephen Ansell, M.D., Ph.D.
Professor of Medicine, Mayo Clinic
Dr. Stephen Ansell is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic. He holds the academic rank of Professor of Medicine, Mayo Clinic College of Medicine. Dr. Ansell received his M.D. and Ph.D. at the University of Pretoria, South Africa and trained in Medical Oncology before coming to the United States. Dr. Ansell completed a residency in Internal Medicine and a fellowship in Hematology and Oncology at Mayo Clinic.
Dr. Ansell’s clinical practice interests focus on non-Hodgkin lymphoma, Hodgkin’s disease, and Waldenstrom’s macroglobulinemia. His research focuses on the biology of the disease, and on developing new therapies. He receives funding for research from the National Institutes of Health, the Leukemia and Lymphoma Society, and the International Waldenstrom’s Macroglobulinemia Foundation.
Dr. Ansell is Chair of the Mayo Clinic Lymphoma Group as well as Chair of the Faculty Development and Recruitment for Hematology at Mayo Clinic. He has been honored with various awards, including the Department of Medicine New Investigator at Mayo Clinic and Medical Honoree at the Lymphoma Research Foundation, Minnesota Chapter. He held memberships with the American Association for Cancer Research, the American Medical Association, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group.
Dr. Ansell has served on the editorial boards of the American Journal of Hematology, Journal of Clinical Oncology, Blood Cancer Journal and Clinical Lymphoma and Myeloma. He has co-authored more than 234 articles in peer-reviewed journals.
Anthony Antonellis, Ph.D.
Associate Professor, Human Genetics, Neurology, University of Michigan
Dr. Anthony Antonellis is Associate Professor of Human Genetics and Associate Professor of Neurology at the University of Michigan.
Dr Antonellis’s research focuses on diseases of the peripheral nervous system including Charcot-Marie-Tooth disease; a neuropathy that mainly affects motor and sensory function in the extremities. His research efforts are divided into two major areas: determining the role of tRNA charging enzymes in axonal peripheral neuropathies, and other inherited human diseases; and, characterizing genes important for Schwann cell development and function.
Samuel (Sandy) Aronson
Executive Director, IT, Partners HealthCare
Mr. Samuel Aronson is the Executive Director of IT for Partners HealthCare Personalized Medicine. Prior to this position, Mr. Aronson worked for Tribiosys as an IT consultant to the biotechnology industry, held several positions with Sapient Corporation, and worked for Monitor Company as a strategic consultant. Mr. Aronson received a Masters degree in Organizational Behavior, and a Bachelors degree in Computer Science from Stanford University, and a Masters in Biology from Harvard Extension School.
Mr. Aronson and his team develops IT infrastructure required to support the evolution, and practice of genetic based personalized medicine in both patient facing, and laboratory settings. The system ecosystem the team maintains enables a real time continuous learning process allowing laboratories to harnesses clinical testing flows to advance knowledge surrounding genetic variation, and keep clinicians up to date through patient specific alerts as they improve variant classifications.
He and his team developed, and continuously enhance the GeneInsight Suite, including the GeneInsight Lab, GeneInsight Clinic, and the functionality that underlies the GeneInsight Network including the VariantWire share-and-share-alike network. The team works with Partners HealthCare Information Systems to maintain the integration between GeneInsight Clinic, and the Partners HealthCare Electronic Health Record.
Mr. Aronson and his team are developing an Olego management system, developed the original GIGPAD system to support laboratory processing including its Case Management System component, and assisting the Partners HealthCare Personalized Medicine Bioinformatics Team in the development, and maintenance of bioinformatic pipeline infrastructure.
Mr. Aronson founded LearningAction, a web-based training company now part of Best Software.
Paldeep Atwal, M.D., MRCP (UK)
Medical Director, Center for Individualized Medicine, Mayo Clinic
Dr. Paldeep Atwal is a clinical, and medical biochemical geneticist and Medical Director of the Center for Individualized Medicine for Mayo Clinic in Florida. He received his M.D. from the University of Glasgow, and trained in hospital internal medicine with The Royal College of Physicians at Glasgow Royal Infirmary in Scotland. He received diplomas in structural molecular biology, and forensic medical science, and completed a genetics fellowship at Stanford University, and a biochemical genetics fellowship at Baylor College of Medicine where he was involved in developing a clinical metabolomic profiling test.
Dr. Atwal’s clinical interests include medical genetics, undiagnosed diseases following lengthy diagnostic odysseys, and inborn errors of metabolism including mitochondrial diseases. He has a long standing interest in rare, and undiagnosed disease including the use of multiple concurrent –omics platforms to provide a diagnosis to patients.
Dr. Atwal’s honors include the 2014-2015 ACMG Foundation/Genzyme Fellowship in Biochemical Genetics Award and The Neurobiology of Disease in Children Young Investigator Award.
Andrew Badley, M.D.
Professor of Medicine, Division of Infectious Diseases, Mayo Clinic
Dr. Andrew Badley is a Professor of Medicine in the Division of Infectious Diseases at Mayo Clinic. Prior to joining Mayo Clinic, Dr. Badley was on staff at Ottawa Hospital in Canada. He returned to the Clinic with his successful research laboratory, and as a consultant in Infectious Diseases. Dr. Badley received an M.D. degree from Dalhousie University in Nova Scotia, and completed his residency, and clinician investigator training in Infectious Diseases at Mayo Clinic.
Dr. Badley’s research receives continuous federal funding, and focuses on the regulation of cell death, and cell survival during infectious diseases, notable HIV, and how understanding these processes can lead to novel therapeutic strategies to reduce morbidity, and mortality. Dr. Badley held numerous leadership positions within Mayo Clinic, including Associate Dean of Research Resources. Currently, Dr. Badley is co-PI, and director of drug discovery for the Mayo Center for Clinical and Translational Sciences, and is Director of the Office of Invention and Translation to Practice.
Dr. Badley has received numerous awards including the Dr. J. Geraci award for excellence in Infectious, the ICAAC / ASM Young Investigator Award, and he holds 2 R01 awards. He holds memberships in the American Society of Clinical Investigation, Fellowship in the American College of Physicians, and the Infectious Diseases Society of America. He served on numerous national, and international scientific committees, including membership on the prestigious NIH Directors Recombinant DNA advisory committee.
He has published more than 120 peer reviewed publications, edited or co-edited 3 books, written numerous book chapters, and holds or has filed several patents related to his work.
Michael Barrett, Ph.D.
Associate Consultant, Department of Research, Mayo Clinic
Dr. Michael Barrett is an associate consultant in the Department of Research at Mayo Clinic in Arizona. He received a B.A. in Political Science and History from Carleton University, a BSc in Biology from University of Ottawa, and a Ph.D. in Molecular Genetics from the University of Toronto.
Dr. Barrett spent seven years at the Translational Genomics Research Institute with a focus on pancreatic cancer genomics. In addition, he spent more than four years with Agilent Technologies as a member of a team of scientists, and engineers that developed a commercially successful life sciences obligonucleotide, and microarray platform.
His lab work has numerous focuses including clonal evolution in progression, and therapeutic responses of pancreatic adenocarcinoma, melanoma, and other solid tumors, development, and application of technologies to allow whole genome interrogation of archived clinical samples, identification of new therapeutic targets in human cancers including triple negative breast cancer, and cholangiocarcinoma.
Dr. Barrett’s research interests include the study of clonal evolution in neoplasia, and cancer in patients with malignant disease or at risk of malignant disease. The fundamental goal of his research is the translation of clonally selected events, such as gene mutations, and amplifications essential for the progression to cancer, as markers, and targets that can be exploited for improved patient care.
Geoffrey Beek, M.S., C.G.C.
Genetic Counselor, Department of Medical Genetics, Mayo Clinic
Mr. Geoffrey Beek is a clinical genetic counselor in the Department of Medical Genetics at Mayo Clinic.
Mr. Beek’s clinical interests include hereditary cancer syndromes, and neurofibromatosis.
He is actively engaged with the Mayo Clinic Center for Individualized Medicine by providing genomic counseling for whole exome sequencing.
Matthew Bernard, M.D.
Associate Professor and Chair of Family Medicine, Mayo Clinic
Dr. Matthew Bernard is an Associate Professor and Chair of the Department of Family Medicine at Mayo Clinic. Dr. Bernard received his M.D. from the University of Minnesota School of Medicine, and completed his Family Medicine residency training at the Mayo School of Graduate Education.
Dr. Bernard has an interest in the education of clinicians on how to practically integrate genomic information into clinical practice. He has developed continuing medical education conferences on genomic medicine in clinical practice.
Nicole Boczek, Ph.D.
Post Doctoral Research Fellow, Mayo Clinic Center for Individualized Medicine
Dr. Nicole Boczek is a Postdoctoral Research Fellow in the Mayo Clinic Center for Individualized Medicine. She received a B.A. in Biology from St. Olaf College, and a Ph.D. in Clinical and Translational Science from Mayo Graduate School.
Dr. Boczek's graduate work focused on the genetic, and molecular basis of cardiac channelopathies. Utilizing whole exome sequencing in combination with functional characterization including patch clamp technique, she identified novel pathogenic variants within the CACNA1C-encoded cardiac L-type calcium channel leading to long QT syndrome, and Timothy syndrome; these techniques were utilized to describe a novel cardiac channelopathy syndrome caused by variants in the CACNA1C gene. Her graduate work was supported by an American Heart Association Predoctoral Fellowship.
Dr. Boczek’s research focuses on functional validation of novel variants of uncertain significance in diagnostic odyssey patients at Mayo Clinic using a variety of laboratory, and bioinformatic techniques along with exploring novel techniques that will aid in patient diagnosis as well as identify novel genetic causes of disease.
Her honors include a Young Investigator Award from the Heart Rhythm Society, and the Courts K. Cleveland SADS Foundation Young Investigator Award in Basic Science.
Stephen Boppart, M.D., Ph.D.
Professor of Engineering, Beckman Institute for Advanced Science and Technology
Dr. Stephen Boppart is an Abel Bliss Professor of Engineering at the Beckman Institute for Advanced Science and Technology, with appointments in the Departments of Bioengineering, Electrical and Computer Engineering, and Medicine. He received his Ph.D. from MIT in Medical Engineering, and his M.D. from Harvard Medical School, later specializing in Internal Medicine and Primary Care.
Dr. Boppart heads the Biophotonics Imaging Laboratory, which is focused on developing innovative optical biomedical imaging technologies, and translating these into clinical applications in medicine, and surgery. His research activities span areas of molecular, and cellular imaging of cancer, tracking in-vivo cell dynamics in skin, and wound healing, point-of-care intraoperative optical imaging of breast cancer tumor margins, and lymph nodes, and primary care imaging of ear infections, and retinal changes in diabetics. He has co-founded three successful start-up companies to commercialize, and disseminate his innovations.
He has helped build a community of faculty, and researchers in imaging science, and technology, with applications across multiple fields of engineering, science, and the arts, and has been directly involved in the development of a new engineering-based College of Medicine on the campus of the University of Illinois at Urbana-Champaign.
Robert Bradley, Ph.D.
Assistant Member in the Computational Biology Program, Public Health and Basic Sciences Division, Fred Hutchinson Cancer Research Center
Dr. Robert Bradley is an Assistant Member in the Computational Biology Program, Public Health Sciences Division, and Basic Sciences Division at Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Bradley received a Ph.D. in Biophysics from the University of California, Berkeley, and completed postdoctoral training at the Massachusetts Institute of Technology.
Dr. Bradley studies RNA biology in human disease, with a focus on identifying new roles for abnormal RNA processing in disease initiation and therapeutic response. Two areas of current interest are mutations affecting RNA splicing factors in myelodysplastic syndromes and nonsense-mediated decay in facioscapulohumeral muscular dystrophy. He is broadly interested in methods to combine and analyze high-throughput sequencing data from research, and clinical settings.
Dr. Bradley’s honors include the New Scholar Award from the Ellison Medical Foundation, and the Dale F. Frey Award from the Damon Runyon Cancer Research Foundation.
Richard Caselli, M.D.
Professor of Neurology, Mayo Clinic College of Medicine
Dr. Richard Caselli is Professor of Neurology in the Mayo Clinic College of Medicine, Associate Director for the Center for Individualized Medicine in Arizona, Associate Director of the Arizona Alzheimer’s Disease Center, and Director of the Clinical Core coordinating the clinical participation of its six member institutions. In addition, he serves on the Alzheimer’s Prevention Initiative committee on genetic disclosure for the upcoming APOE e4 homozygote disease prevention trial.
His earlier appointments included Chair of the Department of Neurology from 2000 to 2010, and member of the Mayo Clinic in Arizona Board of Governors from 2002-2010.
Dr. Caselli’s research programs include cognitive aspects of aging, Alzheimer’s disease, and other forms of dementia. Particular emphasis is focused on the way genetic risk factors for dementia influence how the mind changes with age before the onset of memory loss, and dementia including the preclinical effects of APOE e4 on cognitive aging patterns, and how they differ between healthy aging and preclinical Alzheimer’s disease.
Dr. Caselli received the Mayo Clinic Arizona Distinguished Clinician and Distinguished Investigator Awards, as well as the Lifetime Educator Award.
Wendy Chung, M.D., Ph.D.
Herbert Irving Associate Professor of Pediatrics and Medicine Director of Clinical Genetics, Columbia University
Dr. Wendy Chung is associate professor of pediatrics and medicine, and director of the clinical genetics program at Columbia University. She received her B.A. in biochemistry and economics from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. from The Rockefeller University in genetics.
Dr. Chung’s research focuses on the integration of genetic medicine into all areas of health care. She directs NIH funded research programs in human genetics of obesity, breast cancer, pulmonary hypertension, and birth defects including congenital diaphragmatic hernia, and congenital heart disease.
She was the original plaintiff in the Supreme Court case that overturned the ability to patent genes and is a member of the National Advisory Council for Human Genome Research, and the Genomics & Society Working Group. She has authored over 200 peer reviewed papers.
Dr. Chung received the American Academy of Pediatrics Young Investigator Award, the Medical Achievement Award from Bonei Olam, and a career development award from Doris Duke. She is a member of the Glenda Garvey Teaching Academy, and has won many awards for teaching including the Charles W. Bohmfalk Award for Distinguished Contributions to Teaching, American Medical Women’s Association Mentor Award, and Columbia University Presidential Award for Outstanding Teaching.
Karl Clark, Ph.D.
Assistant Professor, Biochemistry and Molecular Biology, Mayo Clinic
Dr. Karl Clark is an Assistant Professor at Mayo Clinic, and Director of the Center of Individualized Medicine’s Functional Validation Core. Dr. Clark received a B.S. from the University of Wisconsin- Eau Claire in Biochemistry and Molecular Biology. He received a Ph.D. in the Molecular, Cellular, Developmental Biology, and Genetics program from the University of Minnesota, where he trained with Dr. Perry Hackett, and helped develop the Sleeping Beauty transposon system. He moved to Mayo Clinic to work, and train with Dr. Stephen Ekker before starting his own laboratory.
Prior to joining Mayo Clinic, Dr. Clark’s worked at Discovery Genomics, Inc a gene therapy startup in Minneapolis, MN before returning to the University of Minnesota for post-doctoral training in Dr. Scott Fahrenkrug’s laboratory. There he helped improve genome engineering applications in livestock that contributed to starting Recombinetics, Inc, a livestock genome-editing company.
Dr. Clark’s current work with the Functional Validation Core focuses on variants of unknown significance observed in patient genomes that may contribute to disease. Dr. Clark’s research laboratory deploys zebra fish to study the vertebrate stress response system, a diverse suite of neuronal, endocrine, and autonomic response mechanisms that play key roles in environmental interactions. The clinical significance of stress-aggravated disorders is high, but the molecular nature of how stress contributes to disease is largely unknown.
His research goals are to contribute to better understanding of the development of the stress response system, how it impacts patient health, and how it can be modulated for the benefit of patients.
CEO and Co-Founder, GenoSpace
Mick Correll is the CEO and co-founder of GenoSpace. He earned a BS in Computer Science and a BA in Molecular Biology from the University of Colorado, Boulder.
Mr. Correll began his career at Lion Bioscience Research Inc., and UK-based informatics provider InforSense. His career has tracked the path of genomics from basic research to clinical care. He has held leadership positions in academia, and industry, and in the development of informatics solutions for pharma/biotech R&D, ag-bio, and academic, government, and community health care providers.
Prior to launching GenoSpace, Mr. Correll, and GenoSpace partner John Quackenbush established the Center for Cancer Computational Biology at the Dana-Farber Cancer Institute.
Vincenzo Costigliola, M.D.
Founder and President of European Medical Association
Dr. Vincenzo Costigliola received his medical degree from the university of Naples and an honors diploma in Anesthesiology and Intensive Care from the University of Pisa. In addition, Dr. Costigliola has completed studies in Rheumatology, Dermatology, Proctology, Surgery, Drug Abuse, Emergency Treatment, Disaster Action, Hospital Organization, Medical Teaching Methodology, and Computer and Audio-Visual Training for the Medical Profession.
Dr. Costigliola is President of the European Association for Predictive, Preventive, and Personalized Medicine and President of the European Depression Association. He is a Board member of the European Biotechnology Association and a member of the International Advisory Board at King Abdulaziz University in Saudia Arabia. He was selected as expert evaluator in the 5th Framework Program and is the Associate Editor of the European Association for Predictive, Preventive, and Personalized Medicine Journal.
Dr. Costigliola is fluent in Italian, French, English, and Spanish.
Mark Craven, Ph.D.
Professor, Biostatistics and Medical Informatics, University of Wisconsin
Dr. Mark Craven is a professor in the Department of Biostatistics and Medical Informatics at the University of Wisconsin, and an affiliate faculty member in the Department of Computer Sciences. He is Director of the Center for Predictive Computational Phenotyping, one of the NIH's Centers of Excellence for Big Data Computing, and Director of the NIH/NLM-funded Computation and Informatics in Biology and Medicine Training Program.
He is a member of the Institute for Clinical and Translational Research, the Carbone Cancer Center, and the Genome Center of Wisconsin.
Dr. Craven’s research program focuses on the development, and application of machine-learning methods to the problems of inferring models in addition to reasoning regarding networks of interactions among genes, proteins, clinical, and environmental factors, and phenotypes of interest
Kristine Crews, PharmD
Laboratory Director, St. Jude Children’s Research Hospital
Dr. Kristine Crews is Translational Research Laboratory Director in the Pharmaceutical Sciences Department at St. Jude Children’s Research Hospital and Director of the first ASHP-Accredited PGY2 Residency in Clinical Pharmacogenetics. Dr. Crews earned both her B.S. in pharmacy, and her Pharm.D. degree from Rutgers University. She completed a pharmacy practice residency, and a clinical pharmacokinetics specialty residency at the University of Kentucky Chandler Medical Center, and completed a fellowship in clinical pharmacokinetics, and pharmacodynamics at the University of North Carolina and Glaxo Wellcome, Inc.
Her research interests include the clinical implementation of pharmacogenetics to individualize treatment regimens for children with cancer.
Menno Creyghton, Ph.D.
Principal Investigator, Hubrecht Institute
Dr. Menno Creyghton is a principal investigator for Developmental Biology and Stem Cell Research at Hubrecht Institute.
Dr. Creyghton received a Ph.D. at the University of Utrecht for his work at the Netherlands Cancer Institute in the laboratory of Professor Rene Bernards where he worked on functional genetic screens to identify genes in cancer relevant pathways using RNAi. He received a fellowship from the Dutch Cancer Society, and joined the laboratory of Professor Rudolf Jaenisch at the Whitehead Institute for biomedical research at the Massachusetts Institute of Technology where he studied the process of reprogramming adult cells into a stem cell like fate. In addition, he used large scale epigenomic profiling to focus on the massive epigenomic changes that occur at enhancers during cell fate determination.
His research laboratory studies the epigenome during development, and disease in human tissue.
Timothy Curry, M.D., Ph.D.
Education Program Director, Mayo Clinic for Individualized Medicine
Dr. Timothy Curry is the Director of the Education Program of the Mayo Clinic Center for Individualized Medicine, and an Associate Professor of Anesthesiology, and an Assistant Professor of Physiology.
Dr. Curry has a long-standing interest in medical education, and the translation of individualized medicine to the bedside, especially for trainees, and providers new to genomics.
Philip De Jager, M.D., Ph.D.
Associate Professor, Neurology, Harvard Medical School
Dr. Philip De Jager is an Associate Professor of Neurology at Harvard Medical School, and Director of the Program in Translational NeuroPsychiatric Genomics within the Ann Romney Center for Neurologic Diseases in the Department of Neurology at Brigham and Women’s Hospital. He is the first incumbent of the Steven R. and Kathleen P. Haley Distinguished Chair for the Neurosciences.
Dr. De Jager received degrees in Molecular Biophysics and Biochemistry as well as French literature from Yale University, a Ph.D. in Neurogenetics from Rockefeller University, and an M.D. from Cornell University Medical College before completing his M.M.Sc. in Clinical Investigation at Harvard Medical School, and MIT. He served as a Clinical Fellow in Neurology at Brigham and Women’s Hospital, and Massachusettes General Hospital, and is currently a practicing Associate Neurologist at Brigham and Women’s Hospital.
His work focuses on applying modern methods of neuroimmunology, statistical genetics, and computational biology to delineate and intervene in the sequence of events leading from health to neurodegenerative diseases. His discoveries have led to the development of novel tools to enhance clinical decision-making in the diagnosis, and management of patients.
Dr. De Jager studies primarily multiple sclerosis (MS) and age-related cognitive decline. His research projects target four critical areas including: genomic dissection of susceptibility to the onset, and clinical course of MS; genetic epidemiology of cognitive decline, and Alzheimer’s disease; integration of genetic, and biomarker data to identify, and personalize treatment for individuals at high-risk of developing MS or cognitive decline; and integration of multiple brain “omic” data to identify the molecular networks that lead to Alzheimer’s disease as well as drugs that block this process.
Nilüfer Ertekin-Taner, M.D., Ph.D.
Associate Professor, Neurology and Neuroscience, Mayo Clinic
Dr. Nilüfer Ertekin-Taner is Associate Professor of Neurology and Associate Professor of Neuroscience at Mayo Clinic. She received her M.D. from Hacettepe University Medical School in Ankara, Turkey, and her Ph.D., in Molecular Neuroscience from Mayo Graduate School. She completed her neurology residency training, and fellowship in Behavioral Neurology at Mayo Clinic.
Dr. Ertekin-Taner’s laboratory uses biological traits to uncover genetic risk factors for neurodegenerative conditions. Her research aims to discover and characterize genetic factors underlying the complex genetics of Alzheimer’s disease, and related neurodegenerative conditions. Her earlier work contributed to the establishment of the endophenotype approach in genetic studies of Alzheimer’s disease, and pioneered the use of amyloid β peptide levels as an endophenotype in AD genetic research.
Her recent scientific contributions include the completion of one of the largest expression genome-wide association studies (eGWAS) in human brains, which extensively characterized the genetics of human brain gene expression, and their role in human diseases, including Alzheimer’s disease.
An early recipient of the Translational Science KL2 award, Dr. Ertekin-Taner has been continually funded by the NIH, and numerous foundations, and currently leads multiple collaborative projects aimed at gene, and pathway discoveries in Alzheimer ’s disease, and other neurodegenerative diseases.
Robin Everts, Ph.D.
Manager of Applications & Technology Support, Agena Bioscience
Dr. Robin Everts is the Manager of Applications & Technology Support at Agena Bioscience, he oversees the Assays by Agena custom assay development laboratory, and new customer training on the MassARRAY System. He was trained as a molecular geneticist.
Dr. Everts has developed genotyping, somatic mutation analysis, and DNA methylation assays for over 100 applications including pharmacogenetics, and somatic mutation profiling. He is a contributor to the CDC’s Genetic Testing Reference Materials Coordination Program (GeT-RM, Pharmacogenomics workgroup), for which he created, and tested the ADME PGx Pro Panel.
He has published more than 40 peer-reviewed articles on gene expression in immunology, developmental biology, pharmacogenetics, and gene mapping.
Gianrico Farrugia, M.D.
Vice President of Mayo Clinic and CEO, Mayo Clinic in Florida
Dr. Gianrico Farrugia completed his undergraduate training at St. Aloysius College in Birkirkara, Malta, and received his M.D. at the University of Malta Medical School in 1987.
Dr. Farrugia is Vice President of Mayo Clinic and CEO of Mayo Clinic in Florida. He is a consultant in the Division of Gastroenterology and Hepatology and the Department of Physiology and Biomedical Engineering at Mayo Clinic in Rochester, Minnesota as well as a professor of medicine and physiology in the Mayo Clinic College of Medicine. He recently served as the director of the Mayo Clinic Center for Individualized Medicine.
Dr. Farurgia's research interests include genomics, the treatment of disorders of gastrointestinal motility, mechanosensitive ion channels, ion channel regulation, and a cell type known as the interstitial cell of Cajal. He has published more than 250 articles on these topics.
Dr. Farrugia's awards include top teacher awards, Mayo Clinic Research Career Achievement Award and the Janssen Award for Outstanding Science in Gastroenterology.
Matthew Ferber, Ph.D.
Associate Director for Business Development, Mayo Clinic Center for Individualized Medicine
Dr. Matthew Ferber is an Assistant Professor, and Consultant in the Department of Laboratory Medicine and Pathology serving as a Co-Director for both the Clinical Molecular Genetics Laboratory, and the Clinical Genome Sequencing Laboratory. He also serves as the Associate Director for Business Development for the Center for Individualized Medicine at Mayo Clinic.
Dr. Ferber received a Ph.D. in Molecular Biology and Biochemistry at the Mayo College of Medicine Graduate Program, and completed a Post-Doctoral Fellowship in the Clinical Molecular Genetics Laboratory, becoming a Co-Director of the laboratory in 2005.
His research interests include clinical next-generation sequencing, quality assurance, and control in molecular diagnostics, mutation identification in patients with Wilson’s disease, and cancer genetics.
Ian Foster, Ph.D.
Director of the Computation Institute & Argonne Distinguished Fellow
Dr. Ian Foster is the Arthur Holly Compton Distinguished Service Professor of Computer Science at the University of Chicago, an Argonne Distinguished Fellow at Argonne National Laboratory, and the Director of the Computation Institute, a joint unit of Argonne and the University.
He is a fellow of the American Association for the Advancement of Science, the Association for Computing Machinery, and the British Computer Society.
Dr. Foster’s research is concerned with the acceleration of discovery in a networked world.
Dr. Foster’s awards include the British Computer Society's Lovelace Medal, honorary doctorates from the University of Canterbury, New Zealand, and CINVESTAV, Mexico, and the IEEE Tsutomu Kanai award.
Stephen Friend, M.D., Ph.D.
President and Co-Founder, Sage Bionetworks
After receiving a Ph.D. in biophysics, Dr. Stephen Friend completed his clinical training at Children’s Hospital of Philadelphia and the Dana-Farber Cancer Research Institute in Boston. Dr. Friend was on the Harvard Medical School faculty from 1987-1995, Massachusetts General Hospital from 1990-1995 and University of Washington before becoming a Full Member at the Fred Hutchinson Cancer Research Center in 1995. He led the Whitehead Institute, Weinberg lab team to clone the first tumor suppressor gene p53 and characterized its role in controlling the cell cycle.
Dr. Friend and Dr. Leland Hartwell founded and co-led the 'Seattle Project', an institute that developed a method for examining large patterns of genes to provide detailed functional snapshots linking yeast and man and allowed researchers to intuit cellular activity directly from data. By 1997, the Seattle Project evolved into Rosetta Inpharmatics, a company co-founded with Dr. Leroy Hood. Rosetta developed cutting edge tools to generate and analyze high-dimensional functional genomics data, matching genetic variation and function to drug response. Merck & Company acquired Rosetta in 2001 and integrated its approach across the global pharmaceutical enterprise with Dr. Friend as Senior Vice President and Franchise Head for Oncology Research.
In 2009, Dr. Friend and Dr. Eric Schadt co-founded Sage Bionetworks, a non-profit organization with a goal to create a global integrative bionetwork community where researchers are rewarded for collaborating and sharing their data, knowledge and insights.
Dr. Friend continues to actively engage the community to crowd-source solutions to complex biomedical questions through targeted open DREAM analysis challenges.
Naseema Gangat, M.B.B.S.
Assistant Professor, Division of Hematology, Mayo Clinic
Dr. Naseema Gangat is an Assistant Professor of Medicine in the Division of Hematology at Mayo Clinic. She attended medical school at the Aga Khan University in Pakistan, and completed an internal medicine residency, and fellowship training in Hematology and Oncology at Mayo Clinic.
Her clinical, and research interests focus on myeloid malignancies.
Neha Garg, Ph.D.
Postdoctoral Research Associate, Indian Institute of Technology
Dr. Neha Garg is a postdoctoral research associate at the Indian Institute of Technology in Delhi, India. She received a B.S. from Panjab University, and an M.S. (Biochemical Engineering and Biotechnology) from Indian Institute of Technology, and a German academic exchange DAAD fellowship to conduct her thesis research at Technical University of Berlin focusing on characterizing laccases from fungal sources. She received her Ph.D. from the University of Illinois Urbana/Champaign, and worked under the guidance of Professor Wilfred A. van der Donk studying biosynthetic pathways, and structure-activity relationship of lantibiotics.
Dr. Garg joined the laboratory of Professor Pieter C. Dorrestein’s in 2013 as a postdoctoral research associate, and is interested in developing spatial microbiome, and metabolome models of human explant lungs associated with cystic fibrosis. Such models enable visualization of complex host-microbe, and microbe-microbe interactions that exist in complex diseases.
Olga Golubnitschaja, M.D.
Head of the Division Molecular and Experimental Radiology, Department of Radiology, University of Bonn
Dr. Olga Golubnitschaja is on the medical faculty and head of the Department of Radiology of Bonn University. She has studied journalism, biotechnology and medicine and has been awarded fellowships for biomedical research in Pediatrics and Neurosciences in Austria, Russia, United Kingdom, Germany, Netherlands, and Switzerland.
Dr. Golubnitschaja is well-cited in the research fields of “gene hunting” and “subtractive hybridization” applied to predictive prenatal and postnatal diagnostics published as O.Labudova in 1990-2000. She is an expert in molecular diagnostics actively publishing in numerous fields. She is the co-founder of the Theory of Individual Patient Profiles, author of Fundamental Works in Systems Medicine - holistic approach considering molecular patterns at epi\genomic, transcriptional and post\translational levels.
Dr. Golubnitschaja holds appointments, at the rank of Professor, at several European universities and in International Programs for Personalized Medicine and has authored more than 300 international publications in the field.
Dr. Golubnitschaja is the recipient of numerous prestigious awards including the National & International Fellowship fo the Alexander von Humboldt-Foundation; Highest Prize in Medicine and Eiselsberg-Prize in Austria. She is Secretary-General of the European Association for Predictive, Preventive and Personalized Medicine and she is Advisor and Evaluator of projects dedicated to personalized medicine at the EU-Commission in Brussels, NIH/NCI, Washington D.C., and Foundations and National Ministries of Health in several European countries.
Kevin Halling, M.D., Ph.D.
Associate Professor, Mayo Clinic
Dr. Halling is Associate Professor, and Vice Chair for Research and Development for the Mayo Clinic Department of Laboratory Medicine and Director for the Clinical Molecular Genetics Laboratory which performs molecular oncology and hereditary disorder testing. He received a Ph.D. in Biochemistry, and an M.D. at the University of Kansas, and completed an Anatomic and Clinical pathology residency, and Clinical Molecular Genetics fellowship at Mayo Clinic.
Dr. Halling’s area of interest is the development of genetic tests used in the diagnosis and treatment of sporadic and hereditary cancer. He is working with a research team on the development of a clinical RNA Seq assay that can be used to detect gene fusions in patients with various types of malignancies.
Dr. Halling has published over 100 papers, many focusing on genetic testing of cancer.
Thomas Hankemeier, Prof. Dr.
Professor of the Division for Analytical Biosciences, Leiden University
Dr. Thomas Hankemeier is full professor, and Head of the Division for Analytical Biosciences at the Leiden Academic Centre for Drug Research at Leiden University. He received an MSc in Chemistry (cum laude) in Germany, and a Ph.D. in Analytical Chemistry at the Free University in Amsterdam.
Dr. Hankemeier’s research is aimed at innovative analytical tools for metabolomics-driven systems biology in personalized health strategies. In collaboration with clinicians, biomedical researchers, biostatisticians, and other –omics researchers, he works on early diagnosis, and interventions for cardiovascular, neurological, and metabolic diseases.
He established a Metabolomics Facility at Leiden University, in which more than 2000 metabolites, and lipids are measured routinely according to a quality system (ISO 17025) in more than 15,000 clinical, and preclinical samples per year.
Dr. Hankemeier is considered a pioneer in the field of metabolomics, and discovered explorative biomarkers for healthy aging, predicting treatment outcome, predicting clinical endpoints or to identify sub-groups of diseases.
He has obtained various grants (EU, STW, NWO, KNAW, NIH) over the last 8 years and is co-founder of Mimetas, a Leiden-based microfluidics company focusing on high-throughput organ-on-a-chip systems for predictive toxicology testing, efficacy screening, and personalized therapy.
He was a member of the Board of Directors of the International Metabolomics Society, and is a regular participant of NIH, and NWO review panels.
Dr. Hankemeier is co-author of 99 scientific papers, one patent, and 8 patent applications.
Jim Heath, Ph.D.
Professor of Chemistry, Caltech and Professor of Molecular and Medical Pharmacology, UCLA
Dr. Jim Heath is the Elizabeth Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular and Medical Pharmacology at UCLA. He received his Ph.D. from Rice University and was the principle graduate student involved in the discovery of C60, and the fullerenes. Dr. Heath was a Miller Fellow at UC Berkeley before joining the research staff at IBM Watson Labs in 1991. He took a faculty position at UCLA in 1994, and moved to Caltech in 2003.
Dr. Heath directs the National Cancer Institute funded NSB Cancer Center.
He received the Irving Weinstein Award from the American Association of Cancer Researchers, and the Sackler Prize in the Physical Sciences.
Dr. Heath was named by Forbes in 2009 as one of the top 7 innovators in the world.
Elaine Holmes, Ph.D.
Professor of Chemical Biology, Imperial College
Dr. Elaine Holmes is a Professor of Chemical Biology at Imperial College, and Head of the Division of Computational and Systems Medicine.
Dr. Holmes’s main research area focuses on applying metabolic profiling, and computational modeling of biofluids, and tissues to understand pathological, and physiological disease processes. In addition, she is driving new methods for the integration of metabonomic data with proteomic, and transcriptomic data in order to gain a holistic overview of disease process. She has particular interest in the identification of biomarkers of metabolic diseases, and obesity, and much of her current work focuses on the role of the microbiota in promoting obesity.
She is a founding director of Metabometrix, an Imperial College spin-out company, and is a visiting professor at Sam Pablo Universidad CEU Madrid, King AbdulAziz University Saudi Arabia, and the Chinese Academy of Sciences Wuhan China.
Dr. Holmes has authored more than 350 papers in metabonomics.
Matthew Huentelman, Ph.D.
Associate Professor, Neurogenomics Division, Translational Genomics Research Institute
Dr. Matthew Huentelman is Head of the Neurobehavioral Research Unit of the Translational Genomics Research Institute in Phoenix, Arizona. He received a B.S. from Ohio University’s Department of Chemistry and Biochemistry at Clippinger Laboratories, and completed his doctoral work for the University of Florida's Department of Physiology and Functional Genomics at the McKnight Brain Institute where he investigated the application of gene therapy in the study of hypertension.
Dr. Huentelman’s laboratory is focused on the use of cutting edge molecular genomics approaches to earlier diagnose, and more effectively treat diseases of the nervous system. Specific focus areas include rare neurological disease such as undiagnosed childhood disorders, Multiple System Atrophy, Alzheimer's disease, age-related dementias, and normal cognitive aging.
Dr. Huentelman's career includes visiting researcher stints at Moscow’s MV Lomonosov Moscow State University “Biology Faculty”, and in the United Kingdom at the University of Bristol’s Department of Physiology.
He has published over 100 peer-reviewed manuscripts in the scientific literature, and his research is supported in part by the National Institutes of Health - NINDS and NIA, the Arizona Community Foundation, the Institute for Mental Health Research, Science Foundation Arizona, Flinn Foundation, and the State of Arizona DHS.
Sangeetha Iyer, Ph.D.
Scientist, Perlstein Lab
Dr. Sangeetha Iyer received her Ph.D. in Molecular Pharmacology from the University of Pittsburgh and completed her postdoctoral research at the University of Texas.
Her graduate work focused on the generation of genetically engineered mouse models to investigate neurobehavioral pathways and drug interactions critical to alcoholism. Her postdoctoral tenure focused on screening novel peptide modulators and small molecule therapeutics in nematode models of human disease.
Dr. Iyer has more than seven years of experience in model/assay development and drug screening for human disorders across different model systems. At Perlstein lab, she leads efforts on nematode model development and drug screening for rare diseases.
Dr. Iyer is a proponent of public science awareness and has spearheaded crowd funding science efforts as well as created programs to foster interaction between academic and industry circles.
Jin Jen, M.D., Ph.D.
Associate Professor, Department of Laboratory Medicine and Pathology, Mayo Clinic
Dr. Jin Jen is a consultant in the Department of Laboratory Medicine and Pathology at Mayo Clinic, the Co-Director of Mayo Clinic Genome Analysis Core, and a principal member of the Biomarker Discovery Program in the Mayo Clinic Center for Individualized Medicine. She received an M.D. from Beijing Medical College, and a Ph.D. from University of California, San Francisco.
Dr. Jen completed her postdoctoral training at the Johns Hopkins Medical School where she discovered that loss of chromosome 18q is a strong prognostic marker for colorectal cancer. Subsequently, she has published extensively on molecular alterations in cancer, particularly, lung cancer.
She is an expert in genetic analyses of solid tumors, and in gene expression profiling in cancer. Her research focuses on using the next generation sequencing, and single cell based technologies to identify genetic alterations associated with lung, and other cancers, and to investigate their role in tumorigenesis. In addition, she works to develop molecular tests that utilize the knowledge of tumor specific changes to improve cancer diagnosis, prognosis, and treatment stratification in clinical settings.
Dr. Jen has authored or coauthored more than 120 peer reviewed publications, and has patented five inventions. She is an Associate Editor for Clinical Cancer Research, and has served on study sessions for the NIH, and the American Cancer Society.
Dr. Jen is a recipient of research grants from the National Cancer Institute, National Foundation for Cancer Research, and the Mayo Clinic – University of Minnesota Partnership.
Steven Joffe, M.D., MPH
Emanuel and Robert Hart Associate Professor of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine
Dr. Steven Joffe is the Emanuel and Robert Hart Associate Professor of Medical Ethics and Health Policy at the University of Pennsylvania Perelman School of Medicine. He serves as Vice-Chair of the Department, and directs the Fellowship in Advanced Biomedical Ethics. He attended Harvard College, received his M.D. from UC San Francisco, and received his MPH from UC Berkeley. Dr. Joffe trained in pediatrics at UCSF, and in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital.
His clinical work focuses on stem cell transplantation in children. His research addresses the many ethical challenges that arise in the conduct of clinical and translational investigation. He is the principal investigator of studies that examine the roles, and responsibilities of principle investigators in multicenter randomized trials, accountability in the clinical research enterprise, return of individual genetic results to participants in cohort studies, and the integration of genomic sequencing technologies into cancer care.
Dr. Joffe serves as Chair of the Children’s Oncology Group Bioethics Committee, is a member of the U.S. Food and Drug Administration’s Pediatrics Ethics Subcommittee, and a member of the National Academy of Sciences Committee on Federal Research Regulations and Reporting Requirements.
Rima Kaddurah-Daouk, Ph.D.
Associate Professor of Psychiatry and Behavioral Sciences, Duke University
Dr. Rima Kaddurah-Daouk received a Ph.D. in biochemistry from the American University in Beirut and completed a post-doctoral fellowship at the Johns Hopkins Medical School where she worked for two years with Nobel Laureate Dr. Hamilton Smith on the mechanism of protein-DNA recognition.
A co-founder of the Avicena Group, Dr. Kaddurah-Daouk has contributed significantly to the field of energy impairment in disease through her work on the creatine kinase system. With training at Johns Hopkins, Massachusetts General Hospital, Harvard Medical School, and the Massachusetts Institute of Technology, she is credited with several breakthrough inventions that are protected by a portfolio of more than 60 patents and patent applications. A number of these patents are recognized as the industry's earliest patent filings around creatine kinase and energy impairment and neurodegenerative diseases, as well as metabolomics.
Dr. Kaddurah-Daouk serves as the president of the Metabolomics Society, is an adjunct associate professor at Duke University Medical Center and maintains a research affiliation with the Dana Farber Cancer Institute. In addition to co-founding the Avicena Group, she is also credited as a co-founder of Metabolon, another leading biotechnology company.
Dr. Kaddurah-Daouk has key scientific publications in the field of energy impairment in disease. Her collaboration with Dr. M. Flint Beal and others at Harvard Medical School resulted in scientific discoveries that confirmed both the important role of creatine kinase in neuronal cell death and the beneficial effect of creatine supplementation for the potential treatment of ALS and other neurodegenerative diseases.
Javed Khan, M.D.
Deputy Chief and Senior Investigator, National Cancer Institute
Dr. Javed Khan is the Deputy Chief of the National Cancer Institute’s Genetics Branch, and Senior Investigator and Head of the Oncogenomics Section. He is board certified in pediatric hematology and oncology, and continues to attend on clinical service.
Dr. Khan received a bachelor's degree and master's degrees in immunology and parasitology at England's University of Cambridge. He subsequently obtained his M.B> BChir (M.D. equivalent) and the postgraduate degree of M.R.C.P. (Membership of the Royal College of Physicians), equivalent to board certification in the United States. After clinical training in internal medicine, and pediatrics, and subspecialties, he joined the Sanger Center, Cambridge UK; then he joined the Clinical Fellowship Program at the Pediatric Oncology Branch of the National Cancer Institute, and became a tenure track investigator.
His laboratory group is one of the largest on the NIH campus applying Next Generation Sequencing strategies to investigate cancers. Specifically, Dr. Khan’s work focuses on the application of genomic techniques in the investigation of pediatric malignancies, and translating these findings to the clinic. His team has demonstrated that DNA microarray analysis can be used to identify genetic diagnostic fingerprints of cancer, predict the outcome of patients, and the mechanisms of actions of genes, and drugs. He has recently reported on a comprehensive genomic analysis of the rhabdomyosarcoma, and Ewing’s sarcoma genome.
Dr. Khan is leading efforts to develop a Clinical Genomics Platform to enable Precision Medicine for the Center for Cancer Research of the NCI. In addition, he has leadership roles in national efforts including the Therapeutically Applicable Research to Generate Effective Treatments program as well as the Stand up to Cancer St. Baldrick’s Immunogenomics Pediatric Cancer Dream Team.
John Kisiel, M.D.
Assistant Professor, Consultant, Gastroenterology and Hepatology, Mayo Clinic
Dr. John Kisiel is an Assistant Professor of Medicine and Consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic. Dr. Kisiel received his M.D. from the University of Illinois. He completed internal medicine and chief medicine residencies, GI neoplasia and gastroenterology fellowships, and earned a masters degree in Clinical and Translational Research at the Mayo School of Graduate Medical Education.
As a researcher in the GI Cancer Molecular Diagnostics laboratory, Dr. Kisiel’s work is focused on the discovery and clinical development of non-invasive biomarkers for the detection of colorectal, hepatobiliary and pancreatic cancers.
Dr. Kisiel is a member of the Mayo Clinic Center for Individualized Medicine Epigenomic Scientific Committee and Epigenomic Advisory Group and has an active clinical practice in inflammatory bowel disease and gastrointestinal endoscopy.
Eric Klee, M.D., Ph.D.
Assistant Professor, Medical Informatics and Bioinformatics Program, Mayo Clinic
Dr. Eric Klee is an Assistant Professor of Medical Informatics and Bioinformatics Program in the Department of Health Sciences Research. He is Director of Bioinformatics of Mayo Clinic’s Clinical Genome Sequencing Laboratory, and a member of the Department of Laboratory Medicine and Pathology. Dr. Klee is also the Associate Director of Mayo Clinic’s Center for Individualized Medicine Bioinformatics Program, and has directed the Individualized Medicine Bioinformatics team since 2012.
Dr. Klee received a Bachelors of Science degree in Electrical Engineering at Iowa State University, and a Masters of Science degree in Health Informatics with a focus in Bioinformatics at the University of Minnesota. He received a Ph.D. in Health Informatics and Bioinformatics at the University of Minnesota.
His research is focused on the application of next generation sequencing for clinical testing, and diagnostics, and the translation of emerging bioinformatics methods from the research domain into clinical practice.
Dr. Klee is actively involved in the development, and implementation of systems to support sequence analysis, and interpretation in the context of individualized, precision medicine. He leads a functional validation program that uses experimental techniques to better characterize the putative role of variants of uncertain significance in the context of patient-specific disease state.
Irina Kovtun, Ph.D.
Assistant Professor, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
Dr. Irina Kovtun is an Assistant Professor in the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic. She received her Master’s degree, and Ph.D. from Moscow State University. She joined Mayo Clinic as a postdoctoral fellow in 1996, and is currently a member of the Biomarker Discovery Program within the Center for Individualized Medicine.
Dr. Kovtun’s research interests focus on DNA repair, and mutagenesis in cancer, and neurodegenerative diseases. With funding from the NIH, her current research activities include functional analyses of discovered biomarkers for prostate, ovarian, and endometrial cancers. In addition, she is leading studies which utilize genomic analyses of aggressive cancers to identify therapeutic targets, and monitor responses to therapies in the blood using individual patient genomic markers.
She has published her work in high impact journals including Nature Genetics and Nature.
Teresa Kruisselbrink, M.S., C.G.C.
Genetic Counselor, Mayo Clinic Center for Individualized Medicine
Ms. Teresa Kruisselbrink is a genetic counselor supervisor in the Mayo Clinic Center for Individualized Medicine. She is an Instructor of Laboratory Medicine and Pathology, and established the role of the laboratory based genetic counselor in molecular genetics, biochemical genetics, cytogenetics, and maternal serum screening. Ms. Kruisselbrink received a B.S. in Molecular, Cellular, Developmental Biology and Genetics, and a M.S. in Genetic Counseling from the University of Minnesota.
She provides genetic counseling in medical genetics, neurology, obstetrics, cardiology, and outreach clinics.
Ms. Kruisselbrink contributes to numerous educational programs including Mayo Medical School, Graduate School, and fellowship and residency programs in the laboratory and clinical environments. She is also actively involved in mentoring high school, and college students wishing to pursue a career in genetic counseling.
Santosh Kumar, Ph.D.
Associate Professor of Computer Science, University of Memphis
Dr. Santosh Kumar is an Associate Professor of Computer Science at the University of Memphis. He received his Ph.D. in Computer Science and Engineering from Ohio State University where his dissertation won presidential fellowship.
Dr. Kumar is director of the recently awarded NIH Center of Excellence in Mobile Sensor Data-to-Knowledge that involves more than 20 investigators in computing, engineering, behavioral science, and medicine from 11 institutions.
His research interests include mobile sensor systems, and mobile health.
Dr. Kumar was named a “Brilliant Ten”, one of America's ten most brilliant scientists under the age of 38, by the 2010 Popular Science magazine for leading the AutoWitness GPS-less burglar tracking project, and AutoSense wearable sensor project for mobile measurement of stress, and addictive behaviors.
Konstantinos Lazaridis, M.D.
Professor of Medicine and Consultant in the Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine
Dr. Konstantinos Lazaridis is a Professor of Medicine and a Consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic College of Medicine.
Dr. Lazaridis received his medical degree at the University of Ioannina in Greece. He completed his Internal Medicine and Gastroenterology fellowship training at Mayo Clinic and was a Mayo Clinic Scholar in Genomics in the laboratory of Dr. Francis Collins at the National Human Genome Research Institute.
Dr. Lazaridis is considered a leader in the area of the genomics of chronic cholestatic liver diseases, namely, Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Since 2003, he has established and is the principal investigator of the two national consortia for studying patients afflicted with these diseases. Supported by the NIH, Dr. Lazaridis and his research group apply the latest genomic and genetic epidemiology approaches to better understand these diseases and treatment methods.
As Associate Director of the Center for Individualized Medicine in Rochester, Dr. Lazaridis has been instrumental in the establishment and expansion of the Individualized Medicine Clinic and the direction of the Clinomics Translational Program.
Joshua Lewis, Ph.D.
Assistant Professor, University of Maryland School of Medicine
Dr. Joshua Lewis is an assistant professor in the Division of Endocrinology, Diabetes, and Nutrition as well as the Program for Personalized and Genomic Medicine at the University of Maryland School of Medicine. He received his Ph.D. in Molecular Genetics and Genomics at the Center of Genomics and Personalized Medicine Research at Wake Forest University.
Dr. Lewis’s research is identifying and functionally characterizing genes contributing to cardiovascular disease risk and translating genetic discoveries into individualized patient care through pharmacogenomics and/or other clinical approaches. His recent research has shown genetic variants in the Platelet Endothelial Aggregation Receptor 1 (PEARt) gene are associated with platelet reactivity and cardiovascular outcomes in patients on aspirin therapy. He is currently exploring the functional consequences of these polymorphisms in cellular models as well as in human populations.
Dr. Lewis is a member of the NIGMS-funded Pharmacogenomics Research Network and Pharmacometabolomics Research Network. He is the principal investigator of a Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine to investigate the genetic underpinnings and mechanisms underlying aspirin and clopidogrel resistance as well as determining optimal antiplatelet dosing.
His honors include an NIH Extramural Clinical Research LRP Award, a Trainee Research Award from the American Society of Human Genetics, and a Training Fellowship in Cardiovascular Cell Biology from the National Heart, Lung, and Blood Institute.
Noralane Lindor, M.D.
Professor of Medical Genetics, Mayo Clinic
Dr. Noralane Lindor received her M.D. from Mayo Medical School, and trained and practiced as a Family Medicine physician. She completed training in clinical, and molecular genetics, and held positions as clinical geneticist, educator, and researcher in the Department of Medical Genetics at Mayo Clinic in Minnesota Rochester, and since 2012, as researcher in the Department of Health Sciences Research at Mayo Clinic in Arizona.
Dr. Lindor’s research focus has included exploring the feasibility, and impact of integration of new genetic sequencing technologies into the clinical practice.
She has published extensively across a broad range of genetic topics including syndromology and chromosomal disorders, and is best known for her works on the recognition, and risk management of hereditary cancer syndromes.
Edison Liu, M.D.
President and CEO, Jackson Laboratory
Dr. Edison Liu obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University.
Dr. Liu was the founding executive director of the Genome Institute of Singapore and President of the Human Genome Organization from 2007-2013. He held leadership positions as the Scientific Director of the National Cancer Institute's Division of Clinic Sciences, the director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence in Breast Cancer, the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health, chief of medical genetics, and Chair of the Correlative Science Committee of the National Cooperative Clinical Trials Group.
Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology, and translational medicine. He served as Chairman of the Board of Singapore's Health Sciences Authority from 2007-2012 which is the Drug Regulatory Agency for the nation.
He is the recipient of the President's Medal of Singapore for his work to help resolve the SAR's crisis in Singapore and he has authored over 300 scientific papers and reviews, and co-authored two books.
Dr. Liu's current scientific research is focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering the dynamics of gene regulation on a genomic scale that modulate cancer biology.
Ruth Loos, Ph.D.
Director of the Genetics of Obesity and Related Metabolic Traits Program, Mount Sinai Hospital
Dr. Ruth Loos is Director of the Genetics of Obesity and Related Metabolic Traits Program in The Charles Bronfman Institute of Personalized Medicine of the Icahn School of Medicine at Mount Sinai.
Dr. Loos’ primary research interests focus on the identification of genes and genetic loci contributing to the risk of obesity and related metabolic traits and the identification of low-frequency variants through the implementation exome-chip genotyping and sequencing projects in individuals of white European, African, and Hispanic descent. She has actively contributed to many consortia using ‘genome-wide association’ to identify genetic loci for a large number of metabolic traits.
Dr. Loos uses epidemiological methods to follow-up on established loci with the aim to elucidate the pathways through which they increase risk of metabolic disease. Her work also assesses the public health implications of the established loci by examining their predictive value and their interaction with lifestyle factors such as diet and physical activity.
Catalina Lopez-Correa, M.D., Ph.D.
Vice President, Scientific Affairs, Génome Québec
Dr. Catalina Lopez-Correa is the Vice President of Scientific Affairs of McGill University and Génome Québec Innovation Centre. She received an M.D. from the Universidad Pontificia Bolivariana in Colombia, a Master’s degree in Human Genetics from Paris Descartes University in France, a Ph.D. in Medical Sciences from the KULeuven in Belgium, and a mini M.B.A. from McGill University in Canada.
Dr. Lopez-Correa’s primary role is to launch, implement, and manage Génome Québec’s funding programs as well as define the organization’s scientific, and strategic directions. She works closely with government, institutional, and industrial partners to manage more than 40 large scale projects as well as organize national, and international missions, and collaborations with funding agencies, and private sector partners. She manages Génome Québec’s investment in large multicenter genomics projects, and has implemented a new support system to help Québec scientists be highly successful when competing for federal or private funding.
Her experience in the field of scientific innovation expands more than fifteen years in six different countries including the biotech companies Genomica and Informax in the UK, and she serves as Senior Scientist at Eli Lilly and Company in the United States, and deCode Genetics in Iceland.
Dr. Lopez-Correa is a member of several associations in the field of genomics and science innovation. Since 2002, she has served as evaluator for large multinational projects funded by the European Commission, and the NIH and has been recognized with several awards at the national and international level.
Patricia LoRusso, D.O.
Associate Director of Innovative Medicine, Professor of Medicine, Yale Cancer Center
Dr. Patricia LoRusso received her D.O from the Michigan State University School of Osteopathic Medicine and completed a fellowship in Medical Oncology with a focus on developmental therapeutics. She joined the faculty at Wayne State University School of Medicine in 1988. As a result of her focus on early therapeutics, she has come to be recognized as an international expert in the field of Phase 1 clinical research with a focus on novel trial design.
Recently, Dr. LoRusso joined Yale Cancer Center as a Professor of Medicine and Associate Director of Innovative Medicine. She has served as co-chair of the National Cancer Institute’s Cancer Therapy Evaluation Program Investigational Drug Steering Committee. She has served on the scientific committees of the American Society of Clinical Oncology, numerous peer-reviewed study sections, and NCI committees.
Dr. LoRusso has garnered many awards including the American College of Osteopathic Internists Researcher of the Year Award and the Hero of Breast Cancer award. In 2008, she was named one of Crain’s Detroit Business Health Care Heroes, was recognized with the Michaele C. Christian Oncology Drug Development Award and Lectureship from NCI CTEP.
Dr. LoRusso is a former editor of Investigational News Drugs, is currently on the editorial board for Clinical Cancer Research, and is a reviewer for several journals. She has authored more than 200 articles on cancer research in peer-reviewed journals, and written multiple book chapters.
Chris Maher, Ph.D.
Associate Professor of Medicine and Biomedical Engineering, Washington University School of Medicine
Dr. Chris Maher is Assistant Professor of Medicine and Biomedical Engineering at the Washington University School of Medicine, and an Assistant Director of the McDonnell Genome Institute. He received his Ph.D. in Biomedical Engineering through a shared program between Stony Brook University, and Cold Spring Harbor Laboratory, and was a fellow at the University of Michigan Medical School in the Department of Pathology, Center for Computational Medicine and Bioinformatics, and the Michigan Center for Translational Pathology focusing on integrative cancer genomics.
Dr. Maher's area of interest is to integrate bioinformatics, genomics, and cancer biology with the intent of translating genome-based discoveries into the clinic. His research team has focused on the development of novel sequencing strategies, and computational approaches for the detection of aberrant transcription. This has led to multiple pioneering publications highlighting the ability to detect novel gene fusions in solid tumors using Next Generation Sequencing, or RNA-Seq.
His honors include a Prostate Cancer Foundation Young Investigator Award, an NIH Pathway to Independence Award, LUNGevity Foundation Career Development Award, Melissa Lumberg Zagon Founders’ Award, V Foundation V Scholar Award, Cancer Research Foundation Young Investigator Award, Susan G. Komen Career Catalyst Award, and a Prostate Cancer Foundation Global Treatment Sciences Challenge Award.
Elizabeth Mansfield, M.D., Ph.D.
Deputy Director for Personalized Medicine, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health
Dr. Elizabeth Mansfield received her Ph.D., from Johns Hopkins University and completed postdoctoral training at the National Cancer Institute and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases.
Dr. Mansfield has extensive experience in regulation and policy regarding in vitro diagnostic devices where she is developing a program to address companion and novel diagnostic devices. In addition, she has led the development of a personalized medicine program in CDRH.
Previously, Dr. Mansfield served as the Director of Regulatory Affairs at Affymetrix, Inc., 2004-2006, along with Scientific Reviewer, and Genetics Expert.
Svetomir Markovic, M.D., Ph.D.
Professor of Medicine and Oncology and Associate Professor Immunology, Mayo Clinic
Dr. Svetomir Markovic is a Professor of Medicine and Oncology at Mayo Clinic. He holds a joint appointment in Hematology and Oncology, and is an Associate Professor in the Department of Immunology.
Dr. Markovic’s research interests center on translational immunotherapeutics of cancer focused on malignant melanoma, and non-Hodgkin's lymphoma. This work includes development, and clinical testing of cancer vaccines, immune-boosting agents, novel agents that reconstitute immunity in patients with cancer, and combination therapy directed at enhancing anti-tumor immune response.
Christian Marshall, Ph.D.
Associate Director, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children
Dr. Christian Marshall is an Associate Director in the Department of Pediatric Laboratory Medicine at The Hospital for Sick Children, and has an academic rank of Assistant Professor in Laboratory Medicine and Pathobiology at the University of Toronto. He earned his Ph.D. in molecular biology at Simon Fraser University in Vancouver, and completed a post-doctoral fellowship in autism genomics at The Hospital for Sick Children.
His research focuses on the application of new sequencing technologies for identification of human genome variation. Specifically he is interested in the discovery of genomic variation associated with neurodevelopmental disorders such as autism spectrum disorder, schizophrenia, and Attention deficit hyperactivity disorder. As a principal investigator for the Centre for Genetic Medicine’s Genome Clinic, Dr. Marshall is exploring the utility of genome sequencing in pediatric medicine and the translation of new discoveries into clinical diagnostics.
Dr. Marshall’s honors include a Young Investigator Award from the National Alliance for Research in Schizophrenia and Depression. He serves as an associate editor for G3: Genes|Genomes|Genetics and has coauthored over 90 peer reviewed journal articles.
Eric Matey, PharmD, Rph, BCACP
Pharmacist, Hospital Medical Therapy Management, Mayo Clinic
Dr. Eric Matey is a pharmacist at Mayo Clinic. He received a PharmD from Howard University School of Pharmacy. He is a Board Certified Ambulatory Care Pharmacist.
Dr. Matey has worked with Mayo Specialty Pharmacist in charge of Growth Hormone Deficiency, Primary Immune Deficiency, and Hepatitis C, collaborating with specialists to ensure appropriate medication dosing, and patient education for optimal medication experience. In addition, he worked as a Medication Therapy Management pharmacist with interest in pharmacogenomics and Macrobacterium Avium Complex.
Dr. Matey serves as a volunteer at the salvation clinic with Dr. Robert Hoel focusing on diabetes education, and medication management for Minnesota’s underserved patient populations. He is a board member of Africa Partners Medical, a nonprofit organization focusing on stopping needless deaths in Africa.
His professional memberships include MPhA, APhA, ACCP and ASHP.
Robert McCormack, Ph.D.
Head of Circulating Tumor Cell R&D, Janssen Oncology Translational Research and Development, Johnson & Johnson
Dr. Robert McCormack is currently Head of Circulating Tumor Cell R&D and Technology Innovation and Strategy for CellSearch, and next generation technology within the Janssen Oncology R&D Biomarker group. He received a B.S. degree in medical technology from the University of Wisconsin, River Falls, and an M.S. in hematology, and Ph.D. in immunology from the University of Minnesota.
Dr. McCormack’s early career was spent in genetic, molecular, and cellular research at the University of Minnesota, 3M, and Hybritech; he was part of the team that successfully gained FDA approval for PSA in the early detection of prostate cancer. He then joined Sanofi Diagnostics Pasteur as Director of Clinical and Regulatory Affairs, and Worldwide Group Leader for cancer diagnostics. In 1998, he joined Johnson & Johnson as Vice President of Clinical Affairs for Ortho-Clinical Diagnostics, and subsequently was appointed General Manager of the Cellular Diagnostics Group at Veridex, LLC, a Johnson & Johnson start-up dedicated to the development, and commercialization of novel cancer diagnostic tests including the CellSearch CTC test.
Jennifer McCormick, M.D., Ph.D.
Assistant Professor of Biomedical Ethics, Mayo Clinic
Dr. Jennifer McCormick is an Assistant Professor of Biomedical Ethics in the Departments of Medicine and Health Sciences Research. She received her doctorate degree in molecular and cellular biology. She received her Master’s degree in public policy from the University of Michigan. Before coming to Mayo Clinic in 2008, she was a fellow at the Stanford Center for Biomedical Ethics.
Dr. McCormick lectures frequently on topics related to research and translational ethics and directs Mayo Clinic’s graduate school course on Responsible Conduct of Research. She is a primary consultant on the CCaTs Clinical and Translational Research Ethics Consultation Service and works closely with clinical investigators and the IRB to enhance the quality of Mayo Clinic’s research protections.
Dr. McCormick’s scholarly interests focus on topics in research ethics and scientists understandings of policy and social responsibility in context of their work. She has published on topics related to research ethics consultation, genetic and genomic research and biobanking, human research participant engagement and protection, and challenges in translational research.
Dr. McCormick works closely with the Mayo Clinic Center for Individualized Medicine.
D. Holmes Morton, M.D.
Co-Founder, Clinic for Special Children
Dr. D. Holmes Morton is a pediatrician, and the cofounder with his wife Caroline of the Clinic for Special Children in Strasburg Pennsylvania, a non-profit, internationally recognized, medical center that provides care and treatment for children with complex medical problems arising from inherited predispositions to disease.
Dr. Morton received an Honors Biology and Psychology degree from Trinity College, and was elected to Pi Beta Kappa. He studied medicine at Harvard Medical School, and completed a three-year Residency in Pediatrics at Children’s Hospital. Dr. Morton moved to Children’s Hospital of Philadelphia to study biochemical genetics under Richard Kelley, and with the support of Hugo Moser, he moved Dr. Kelley’s new laboratory to Kennedy Krieger Institute at Johns Hopkins to develop methods for diagnosis, and treatment of the Amish variant of Glutaric Aciduria Type 1. This work led to the establishment of the Clinic for Special Children.
He is a member of the American Academy of Pediatrics, and the Society for Inherited Metabolic Disorders, he was awarded the Albert Schweitzer Prize for Humanitarianism, and a John D. and Catherine T. MacArthur Fellowship.
Muhammed Murtaza M.B.B.S.
Assistant Professor and Co-Director, Center for Noninvasive Diagnostics, TGen
Dr. Muhammed Murtaza is an Assistant Professor, and Co-Director of the Center for Noninvasive Diagnostics at TGen, a non-profit research institute in Phoenix, Arizona, and jointly appointed at Mayo Clinic in Arizona. He received a Ph.D. from the University of Cambridge, and an M.B.B.S. from Aga Khan University in Pakistan.
Dr. Murtaza’s group focuses on development of novel methods, and applications for circulating tumor DNA analysis in cancer patients.
He has published groundbreaking studies describing sequencing of circulating tumor DNA for tracking cancer burden, and evolution.
Heidi Nelson, M.D., F.A.C.S., F.A.S.C.R.S.
Professor of Surgery, Mayo Clinic
Dr. Heidi Nelson is the Fred C. Andersen Professor of Surgery at Mayo Clinic, Chair of the Department of Surgery, and past Chair of the Division of Colon and Rectal Surgery. Dr. Nelson earned her medical degree from the University of Washington School of Medicine, completed her General Surgery Residency at Oregon Health and Science University, and her fellowship training in Colon and Rectal Surgery at Mayo Clinic.
Dr. Nelson’s long standing research interests parallel her clinical work in colon and rectal cancer. She was the PI of the NCI-grant, and lead investigator for the NIH-funded laparoscopic colectomy for cancer trial.
Dr. Nelson’s research leadership roles include past program director within the Mayo Clinic Cancer Center, and director of the Mayo Microbiome Program in the Mayo Center for Individualized Medicine. Within the National Cancer Institute Cooperative Groups, she served as Vice Chair of the North Central Cancer Treatment Group, and the Group Chair of American College of Surgeons Oncology Group. She has been faculty for the AACR/ASCO Methods in Clinical Cancer Research Workshop for a three year term, a member, and chair of two NIH (NCI) study sections including, Subcommittee H (Cooperative Group Study Section), Clinical Oncology, and a member of the NCI Clinical Trials Advisory Committee.
She has been the recipient of numerous nationally funded grants, and is widely published in high impact journals.
Wayne Nicholson, M.D., Pharm D
Assistant Professor, Anesthesiology and Pharmacology, Mayo Clinic College of Medicine
Dr.Wayne Nicholson is an Assistant Professor of Anesthesiology and Pharmacology in the Mayo Clinic College of Medicine and a Consultant on the medical staff as a Clinical Pharmacologist in the Department of Anesthesiology.
In addition to licensure in both medicine, and pharmacy practice, he is credentialed by the American Board of Clinical Pharmacology, and the Board of Pharmaceutical Specialties.
Grzegorz Nowakowski, M.D.
Assistant Professor of Medicine, Mayo Clinic College of Medicine
Dr. Grzegorz Nowakowski is a Consultant and Chair of Education in the Division of Hematology at Mayo Clinic, an Assistant Professor of Medicine in Mayo Clinic College of Medicine, and program director of the Hematology/Oncology Fellowship in Mayo School of Graduate Medical Education.
He received his M.D. from the Medical University of Warsaw in Poland. He completed his internal medicine residency at Norwalk Hospital in Norwalk, Conn., and his fellowship in hematology-oncology at Mayo Clinic. Dr. Nowakowski joined the Mayo Clinic lymphoma group in 2006 as a Mayo Foundation Scholar.
His research focuses on molecular classification, biology, and novel therapies of lymphoproliferative disorders. He is the principal investigator of multiple investigator-initiated, and cooperative group clinical trials, and serves as scientific officer in the Academic and Community Cancer Research United where he is responsible for overseeing hematology clinical trials.
Dr. Nowakowski chaired the American Society of Clinical Oncology Lymphoma and Myeloma Education Committee for 2014-2015. He is an alumnus of the American Society of Hematology Clinical Research Training Institute, and served as a member of the ASH Committee on Scientific Affairs.
Tamas Ordog, M.D.
Associate Professor, Physiology, Mayo Clinic
Dr. Tamas Ordog is a Consultant and Associate Professor in the Department of Physiology and Biomedical Engineering and the Division of Gastroenterology and Hepatology at Mayo Clinic and founding Director of the Epigenomics Program of the Mayo Clinic Center for Individualized Medicine. He received predoctoral training in molecular endocrinology at the University of Pees, Hungary and postdoctoral training in integrative neuroendocrinology at the University of Texas Houston Health Science Center.
Dr. Ordog has studied the cellular and molecular basis of gastrointestinal neuromuscular control in health and disease since 1998. His current research interests include the epigenetic control of cellular phenotypes in the lineage of gastrointestinal pacemaker/neuromodulator cells in aging, diabetes, and caloric restriction and oncogenesis in response to targeted oncolytic therapy.
As Director of the Mayo Clinic CIM Epigenomics Program, he is leading the effort to implement epigenomic testing in the Individualized Medicine Clinic.
Casey Overby, Ph.D.
Assistant Professor, University of Maryland School of Medicine
Dr. Casey Overby is an Assistant Professor at the University of Maryland School of Medicine, a member of the Program for Personalized and Genomic Medicine, the Center for Health-Related Informatics and Bioimaging, and an affiliate member of the University of Maryland Institute for Advanced Computer Studies. She is also an Adjunct Investigator in the Genomic Medicine Institute at Geisinger Health System.
Dr. Overby completed pre-doctoral National Library of Medicine biomedical informatics training, and National Human Genome Research Institute genome sciences training fellowships at the University of Washington. She also completed a post-doctoral National Library of Medicine informatics training fellowship at Columbia University.
Her research focuses on areas at the intersection of public health genetics, and biomedical informatics, including applications that support translation of biological knowledge to clinical care, and population health care, delivering health information, and knowledge to the public, and developing knowledge-based approaches to use big data for population health.
Eric Pamer, M.D.
Chief, Infectious Disease Service, Memorial Sloan-Kettering Cancer Center
Dr. Eric Pamer received his medical degree from Case Western Reserve University Medical School and completed clinical training in Internal Medicine and Infectious Diseases at UCSD Medical Center. Before moving to Yale University, he was a postdoctoral fellow with Charles E. Davis at UCSSD, Maggie So at Scripps Research Institute and Michael Bevan at the University of Washington.
In 2000, Dr. Pamer moved his laboratory to Memorial Sloan-Kettering Cancer Center in New York where he has been Chief of Infectious Disease and, more recently, Head of the Division of General Medicine.
Alexander Parker, Ph.D.
Associate Director, Mayo Clinic Center for Individualized Medicine
Dr. Alexander Parker is the Cecelia and Dan Carmichael Family Associate Director of the Center for Individualized Medicine at Mayo Clinic in Florida, vice chair of the Department of Health Sciences Research, and an Associate Professor of Epidemiology, and Urology at the Mayo Clinic College of Medicine.
Dr. Parker received a Masters degree in preventive medicine, and a Ph.D. in epidemiology from the University of Iowa. He completed a National Institutes of Health fellowship in genetic epidemiology at Mayo Clinic, and joined the Mayo Clinic staff as the first epidemiologist on the Florida campus.
Dr. Parker's primary area of interest is advancing the understanding of genitourinary cancer’s causes, and treatment, with a particular focus on identifying, and developing clinically relevant biomarkers to enhance diagnosis, and prognosis of kidney cancer.
He chaired several national study section panels, and currently serves as the principal investigator on five extramural grants, including funding from the NIH, the National Cancer Institute, the Department of Defense, the state of Florida, and the James and Esther King Biomedical Research Program.
Dr. Parker was integral in establishing the Individualized Medicine Clinic at Mayo Clinic in Florida.
Mrinal Patnaik, MBBS
Consultant and Assistant Professor of Oncology and Internal Medicine and Consultant in the Division of Hematology, Mayo Clinic
Dr. Mrinal Patnaik is a Consultant in the Division of Hematology and the Department of Internal Medicine at Mayo Clinic. He serves as a clinical consultant in hematological malignancies, and allogeneic stem cell transplantation, and is the current program director for the Bone Marrow Transplant Fellowship. He is the Myeloid Director for the Mayo Clinic Center for Individualized Medicine, and has a special interest in epigenetic dysregulation in myeloid malignancies.
Dr. Patnaik received his MBBS from Grant Medical College in India. He completed an internal medicine residency at the University of Minnesota, and a Fellowship in Hematology, Oncology and Bone Marrow Transplant at Mayo Clinic.
Dr. Patnaik has authored numerous publications on myeloid neoplasms, with particular focus on myelodysplastic Syndromes, and chronic myelomonocytic leukemia. He has documented the adverse prognostic impact of ASXL1 gene mutations in myeloid neoplasms. This seminal work has resulted in the development of the Molecular Mayo Prognostic model for patients with CMML.
He received the CTSA KL2 award for furthering his training in epigenetics, and cancer biology and the Margret Landenberg Foundation award for studying the effect of oncolytic viruses in blood cancers.
Katherine Payne, Ph.D.
Professor of Health Economics, Manchester Center for Health Economics
Ms. Katherine Payne received her clinical pharmacy degree from Keel University, her Master of Science in Health Economics degree from York University, and her Doctor of Philosophy in Pharmacy Practice degree from Manchester University. She served as the health economist for the North West Genetics Knowledge Park (Nowgen) between 2003 and 2007, and in 2010 was awarded a personal chair in health economics at The University of Manchester.
Ms. Payne was awarded a five-year Research Councils UK Academic Fellowship in Health Economics to focus on the evaluation and valuation of genomic technologies including genomic-based diagnostics, and pharmacogenetic tests. Her recent projects include: evaluating an integrated model of service delivery for inherited retinal dystrophies, economic evaluation of personalized breast screening programs, preliminary economic evaluation of high-throughput whole genome sequencing technologies, economic evaluations of different applications of pharmacogenetic testing, and the application of stated preference methods, including discrete choice experiments.
Ms. Payne was a member of a NICE Technology Appraisal Committee. She holds honorary positions with the School of Pharmacy, University of Nottingham, PHG Foundation, Cambridge, Central Manchester University Hospitals NHS Foundation Trust, and Nowgen, Manchester.
Naveen Pereira, M.D., F.A.C.C.
Assistant Professor, Medicine and Pharmacology, Mayo Clinic College of Medicine
Dr. Naveen Pereira is a Consultant for the Division of Cardiovascular Diseases and Assistant Professor of Medicine and pharmacology, Mayo Clinic College of Medicine. He is board certified in Internal Medicine, cardiovascular diseases and advanced heart failure and transplant.
Dr. Pereira earned his medical degree at University of Bombay. He completed his internship and residency at the University of Connecticut and cardiac fellowship at the Brown University Hospital System and Massachusetts General Hospital.
Dr. Pereira received the Mayo Clinic Department of Medicine Career Development Award, the Marie Ingalls Cardiovascular Career Development Award, the Academic Research in Cardiology Award, the Transplant Center Scholarly Program Award, the Clinical Immunology and Immunotherapeutic Program Award and the Clinical and Translational Sciences KL2 Award with a focus on translating the genetics of pharmacotherapy.
Dr. Pereira served as Chairperson of the Standards and Guidelines Workforce of the International Society of Heart and Lung Transplantation. He is a member of the Functional Genomics and Translational Biology Council of the American Heart Association and is a member of the Circulation: Cardiovascular Genetics editorial board.
Dr. Pereira’s research interest include treatment of end-stage heart failure, antibody-mediated rejection in heart transplant, cardiac allograft hypertrophy, and genetics of the natriuretic peptide system and pharmacogenomics.
Josh Peterson, M.D., M.P.H.
Associate Professor of Biomedical Informatics and Medicine, Vanderbilt University School of Medicine
Dr. Josh Peterson is an Assistant Professor of Biomedical Informatics and Medicine at Vanderbilt University School of Medicine. Dr. Peterson received an M.D. from Vanderbilt University School of Medicine, completed an Internal Medicine residency at Duke University Medical Center, completed a fellowship in General Internal Medicine at the Brigham and Women’s Hospital, and received a Masters of Public Health degree at the Harvard School of Public Health. He practices internal medicine at the Vanderbilt Adult Primary Care Clinic.
Dr. Peterson played a pivotal role in developing and evaluating clinical decision support to improve drug safety and efficacy, and to translate genomic technologies to routine clinical care. He directs the development and evaluation of clinical decision support for Vanderbilt University Medical Center’s pharmacogenomics quality improvement initiative – PREDICT (Pharmacogenomic Resource for Enhanced Decisions In Care and Treatment). He currently leads research funded by NHLBI, NHGRI, CDC, and PGRN to evaluate the implementation of PREDICT including both clinical and cost effectiveness.
He has published more than 50 peer-reviewed papers, participates as principle or co-investigator on four federally funded projects, and has completed work on an additional 14 funded projects as PI or co-investigator.
Kathryn Phillips, Ph.D.
Professor, School of Pharmacy, University of California, San Francisco
Dr. Kathryn Phillips is the founding director of the Center for Translational and Policy Research on Personalized Medicine in the School of Pharmacy at the University of California, San Francisco. She is also a professor of health economics, and health services research in the Department of Clinical Pharmacy with additional appointments in the Philip R. Lee Institute for Health Policy Studies, and Helen Diller Family Comprehensive Cancer Center.
Dr. Phillips is a health services researcher, health economist, and leader in the application of new technologies to improve health care. Her focus is on issues around access, quality, and value of new technologies. Her core specialty is personalized medicine with her work spanning multiple disciplines, including basic, clinical, and social sciences, and mobilizing experts in academia, industry, health care, payers, and government.
She led one of the earliest studies on pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001), and her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).
Dr. Phillips has served on national and international scientific advisory committees, and workshops including work for GenomeCanada, Institutes of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, and the President’s Council of Advisors on Science and Technology. She has served as an advisor to various international, and industry organizations, including more than 35 biotechnology companies, and venture capital firms.
She is a member of the editorial board of the journal Health Affairs, and several leading journals on personalized medicine. She has published more than 100 peer-reviewed articles in major journals, including JAMA, the New England Journal of Medicine, and Health Affairs.
For more than 25 years, Dr. Phillips has received funding from the US. National Institutes of Health as a principal investigator.
Cindy Powell, M.D.
Professor of Pediatrics and Genetics, University of North Carolina
Dr. Cindy Powell is a Professor of Pediatrics and Genetics at the University of North Carolina at Chapel Hill School of Medicine, and a board-certified clinical geneticist, clinical cytogeneticist, pediatrician, and genetic counselor. She is Director of the Medical Genetics Residency Program, Medical Director of the Cytogenetics Laboratory, and an investigator in the Carolina Center for Genomics and Society, a Center for Excellence in ELSI Research sponsored by the National Institutes of Health.
Dr. Powell received a B.S. in Biology from Cornell University, a Master’s degree in Human Genetics from Sarah Lawrence College, and an M.D. from the Medical College of Virginia. She completed a pediatric residency at Children’s National Medical Center in Washington, DC, and a medical genetics fellowship at Children’s National Medical Center, and the National Institutes of Health.
Her clinical and research interests include dysmorphology, genetic syndromes, and ethical issues of genetic testing, and newborn screening. She is the principal investigator of a project funded by NIH to examine the use of next-generation sequencing for newborn screening.
Dr. Powell is past President of the American Board of Medical Genetics, served on the Medical Genetics Resident Review Committee of the Accreditation Council of Graduate Medical Education, and on the Executive Committee of the Section on Genetics and Birth Defects of the American Academy of Pediatrics.
Stephen Quake, DPhil
Professor, Bioengineering, Stanford University
Dr. Stephen Quake is a professor of bioengineering and applied physics at Stanford University. He earned his BS in physics and his MS in mathematics at Stanford and a doctorate in theoretical physics from Oxford University as a Marshall Scholar. He returned to Stanford University, where he spent two years as a postdoc in Steven Chu's group.
Dr. Quake joined the faculty of the California Institute of Technology in 1996, and was appointed the Thomas and Doris Everhart Professor of Applied Physics and Physics. He received “Career” and “First” awards from the National Science Foundation and NIH and was named a Packard Fellow. These awards supported a research program that began with single molecule biophysics and expanded to include the inventions of single molecule sequencing and microfluidic large scale integration, and their applications to biology and human health.
He returned to Stanford University in 2005 to help launch a new department in Bioengineering where he is now the LeeOtterson Professor and an investigator of the Howard Hughes Medical Institute. His interests lie at the nexus of physics, biology, and biotechnology. His research is concerned with developing new approaches to biological measurement and applying these approaches to problems of both fundamental and medical interest. Areas of interest include genomic diagnostics, systems biology, microbial ecology, and single cell genomics.
Dr Quake’s honors include the Human Frontiers of Science Nakasone Prize, the MIT-Lemelson Prize, the Raymond and Beverly Sackler International Prize in Biophysics, the American Society for Microbiology Promega Biotechnology Research Award, the Royal Society of Chemistry Publishing Pioneer of Miniaturization Award, and the NIH Director’s Pioneer Award.
Dr. Quake is an elected fellow of the American Academy of Arts and Sciences, the National Academy of Inventors, the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, the American Institute for Medical and Biological Engineering, and the American Physical Society.
Eric Reiman, M.D.
Professor of Psychiatry, University of Arizona
Dr. Eric Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Clinical Director of Neurogenomics at the Translational Genomics Research Institute, and Director of the Arizona Alzheimer’s Consortium.
Dr. Reiman received his undergraduate and medical degrees at Duke University. He completed his psychiatry residency training at Duke University and Washington University and his introduction to brain imaging research at Washington University.
Dr. Reiman is internationally recognized for his contributions to brain imaging research, the behavioral neurosciences, and the presymptomatic study of Alzheimer’s disease. He has developed a strategy to find demonstrably effective treatment to prevent Alzheimer’s disease.
Dr. Reiman has authored more than 250 publications. He is a principal investigator of several NIH-supported research programs, and a leader of the Alzheimer’s Prevention Initiative.
Jason Rihel, Ph.D.
Senior Research Fellow, Department of Cell and Developmental Biology, UCL
Dr. Jason Rihel is a Senior Research Fellow in the Department of Cell and Developmental Biology at UCL. He started his career in behavioral genetics as an undergraduate in Dr. Jeff Price’s lab at West Virginia University by investigating the fruit fly circadian clock mutant, double-time. After graduating summa cum laude with Honors, he joined Dr. Catherine Dulac’s lab for his Ph.D. studies at Harvard University.
Dr. Rihel completed a Howard Hughes Medical Institute predoctoral fellowship in the Dulac lab where he developed sensitive methods to observe gene expression in single cells, which he applied to studies on the molecular underpinnings of mouse pheromone detection. He cultivated his current research interests, understanding the genes and neurons that regulate sleep in zebrafish, while a Bristol-Myers Squibb Life Sciences Research Fellow in Dr. Alexander Schier’s lab, first at the Skirball Institute at the NYU School of Medicine and then at Harvard University.
His research at UCL is currently funded by a 3-year UCL Excellence Fellowship, and a 5-year starter grant from the European Research Council.
Veronique Roger, M.D.
Professor of Epidemiology and Professor of Medicine, Mayo Clinic
Dr. Veronique Roger received her M.D., from the Paris, France Medical School and her M.P.H., from the Minnesota School of Public Health. At Mayo Clinic, she is a Professor of Internal Medicine, a Professor of Epidemiology, a cardiologist, an epidemiologist, and an outcomes researcher.
Dr. Roger’s research program focusing on the occurrence and outcomes of cardiovascular diseases is closely linked with the internationally recognized Rochester Epidemiology Project, and has been funded by the NIH since 1996.
Dr. Roger serves in several leadership roles within Mayo Clinic and is a member of the Mayo Clinic Board of Governors and Board of Trustees. In her role as Director of the Mayo Clinic Center for the Science of Health Care Delivery, Dr. Roger oversees several initiatives relevant to the research use of clinical data in the electronic health record environment including the Rochester Epidemiology Project and the High Value Health Care Collaborative.
Dr. Roger serves on national committees and task forces at the American Heart Association, the Institute of Medicine and the National Institutes of Health where she is a member of the National Heart, Lung and Blood Advisory Council.
Jonathan Rosenberg, M.D.
Associate Attending Physician, Memorial Sloan Kettering Cancer Center
Dr. Jonathan Rosenberg is an Associate Attending Physician at Memorial Sloan Kettering Cancer Center, and the Section Head for Non-Prostate Genitourinary Malignancies.
Dr. Rosenberg’s work focuses on correlating novel genomic findings with clinical outcomes in bladder cancer, as well as developing, and testing novel treatment strategies in bladder cancer.
Sushmita Roy, Ph.D.
Assistant Professor, Biostatistics and Medical Informatics and Wisconsin Institute for Discovery, University of Wisconsin
Dr. Sushmita Roy is an assistant professor in the Department of Biostatistics and Medical Informatics and the Wisconsin Institute for Discovery at the University of Wisconsin. She received her Ph.D. from the University of New Mexico, and a post-doctorate degree at the Broad Institute of MIT and Harvard.
Dr. Roy’s lab focuses on the development, and application of statistical machine learning methods to problems in regulatory genomics. Particular focus is placed on building network-based predictive models in developmental, and evolutionary lineages.
Dr. Roy received the 2014 Alfred P. Sloan Foundation Fellowship award, and an NSF CAREER award.
Head of Bioinformatics, Affymetrix
Mr. Anthony Schweitzer is the Head of Bioinformatics for the Expression Business Unit of Affymetrix, and oversees the bioinfomatic needs of scientists throughout research, and development. Mr. Schweitzer received a Bachelors of Science degree in molecular biology focusing on bioinformatics of progenitor stem cell research from Ohio State University. Prior to his work with Affymetrix, he worked in San Francisco on pharma, and biotech clinical target discovery programs in the areas of asthma and diabetes. Mr. Schweitzer became the Director of Bioinformatics and IT for Metabolex Inc., and began working with Affymetrix to develop custom expression arrays. He became the head of the Affymetrix laboratories Expression R&D informatics team, and worked extensively on developing whole transcriptome expression microarrays.
Mr. Schweitzer actively participates in the US FDA SEQC/MAQC-III consortium, and educates on the power, and limitations of RNA-seq. He has given lectures, and seminars throughout the world sharing insights on transcriptomics, biomarker discovery, and clinical use of microarrays for personalized medicine.
Richard Sharp, Ph.D.
Director of Biomedical Ethics, Mayo Clinic
Dr. Richard Sharp is Director of Mayo Clinic’s Biomedical Ethics Program. Prior to joining Mayo Clinic, he was Director of Bioethics Research at Cleveland Clinic, and Co-Director of the Center for Genetic Research Ethics and Law at Case Western Reserve University, one of six NIH Centers of Excellence in Ethics Research.
Dr. Sharp’s current research includes examining how patients, and health care providers view new forms of personalized medicine, and clinical interventions enabled by molecular diagnosis.
He frequently advises health care organizations on ethical issues, and has served on advisory committees for the National Institutes of Health, Institute of Medicine, American College of Medical Genetics, and the US Environmental Protection Agency.
Dr. Sharp is widely published on topics in biomedical ethics, including clinical ethics consultation, informed consent, financial conflicts of interest, and ethical tensions in patient advocacy.
Saurabh Sinha, Ph.D.
Associate Professor, Computer Science, University of Illinois
Dr. Saurabh Sinha is an Associate Professor of Computer Science at the University of Illinois, Urbana-Champaign.
Dr. Sinha’s research interests include computational regulatory genomics, cis-regulatory evolution, pharmacogenomics, and big-data for genomics.
He is the Education Lead for the Mayo-Illinois Alliance, and serves as Research PI on the NIH BD2K Center at Illinois.
Diane Slusarski, Ph.D.
Professor, Department of Biology, University of Iowa
Dr. Diane Slusarski is a Professor in the Department of Biology at the University of Iowa, and a faculty member of the Wynn Institute for Vision Research. She received a Ph.D. in Cell and Molecular Biology from Northwestern University, and a National Research Service Award for postdoctoral training in Developmental Genetics at The Johns Hopkins University.
Dr. Slusarski’s research focuses on the signal transduction mechanisms that shape the vertebrate embryo. Studies from her group characterize the mechanisms by which the genes associated with disease, and interacting biochemical pathways are coordinated for proper development, organogenesis, and visual function.
Her lab uses zebrafish whose transparency, and rapid development facilitate understanding normal organogenesis, and disease pathophysiology. By coupling in vivo physiological imaging of calcium release dynamics with manipulation of signaling components, Dr. Slusarski established roles for Wnt and calcium in axial patterning, directed cell migration, retinal structure, and organ laterality. Her lab has developed the zebrafish as a model for human disease including ciliopathies, such as Bardet Biedl Syndrome (BBS), blinding disorders, and epilepsy.
Dr. Slusarski received the Basil O’Connor Research Scholar Award, and Collegiate Teaching Award. She has maintained an externally funded research program for over 15 years.
Jun Song, Ph.D.
Professor of Bioengineering, Professor of Physics, University of Illinois
Dr. Jun Song is Founder Professor of Bioengineering and of Physics at the University of Illinois, Urbana-Champaign (UIUC). Prior to joining UIUC, he was a faculty member in the Department of Epidemiology and Biostatistics at the University of California, San Francisco. Dr. Song received an A.B. degree in Physics from Harvard University, a Master’s degree in Mathematics from University of Cambridge, and a Ph.D. in Mathematical Physics from M.I.T.
His research program revolves around statistical methodology development for analyzing and integrating high-throughput genomic data, especially in the contexts of epigenetics and cancer.
Dr. Song is a co-PI of the NIH Center of Excellence in Big Data Computing at UIUC.
Paul Takahashi, M.D.
Consultant and Professor of Medicine, Internal Medicine, Mayo Clinic
Dr. Paul Takahashi is a Professor of Medicine within the Department of Internal Medicine and a primary care internist and geriatrician at Mayo Clinic. He received his M.D. from the University of Illinois and completed his medical training in internal medicine and geriatrics at Mayo Clinic. Dr. Takahashi received a Masters of Public Health from the University of Minnesota in and currently serves as the co-medical director for the Mayo Clinic Biobank.
His research interests involve risk stratification for hospitalization using novel predictors including pharmacogenomics and socioeconomic status. His study includes new models of care delivery including telemedicine, care transitions, and palliative home care.
Dr. Takahashi’s educational efforts include training Mayo Clinic geriatric fellows, residents, and medical students.
He is a fellow of the American College of Physicians, and the American Geriatrics Society.
Cole Trapnell, Ph.D.
Assistant Professor, Genome Sciences, University of Washington
Dr. Cole Trapnell is an Assistant Professor in the Department of Genome Sciences at the University of Washington. Dr. Trapnell received a Bachelor's degree, and a Ph.D. in Computer Science from the University of Maryland. As a graduate student, he was co-advised by Steven Salzberg, and Lior Pachter from the University of California, Berkeley. While working with Steven and Lior, he wrote TopHat and Cufflinks, and helped Ben Langmead with Bowtie.
He trained as a postdoc in John Rinn's lab at Harvard's Department of Stem Cell and Regenerative Biology, and worked with Davide Cacchiarelli on Monocle.
Dr. Trapnell studies cell differentiation, reprogramming, and cell-cell communication. He also develops technologies to help identify genes that regulate these processes.
Raul Urrutia, M.D.
Professor of Biophysics, Mayo Clinic
Dr. Raul Urrutia is Professor of Medicine, Biochemistry and Molecular Biology, and Biophysics at Mayo Clinic. He graduated Magna Cum Laude in 1987 from Cordoba University Argentina and pursued postdoctoral training at the National Institues of Health in Bethesda Maryland.
Dr. Urrutia established a laboratory at Mayo Clinic dedicated to studying chromatin dynamics and epigenetics as applied to metabolism and cancer. His laboratory discovered several HDAC, HATs, and HMTs pathways that associate with the development of diabetes and pancreatic cancer. His current work is focused on the functional characterization of HMT pathways, in particular G9a, GLP, SUV39H1, and EZH2.
Dr. Urrutia has published highly influential original articles, book chapters, reviews, and a widely cited textbook on pancreatic cancer. He has served as the Editor-in-Chief for three journals, Pancreatology, International Journal of Gastrointestinal Cancer, and Case Reports in Gastroenterology. He is a member of several editorial boards including the Journal of Biological Chemistry, Medical Epigenetics, and Pancreatology and Pancreas.
Dr. Urrutia served as President for the American Pancreatic Association, Chair for Pancreatic Diseases Section for the American Gastroenterological Association, and Chair for the International Association of Pancreatology board.
J. Craig Venter, Ph.D.
Co-Founder, Executive Chairman, and CEO of Human Longevity Inc., J. Craig Venter Institute, and Synthetic Genomics
Dr. J. Craig Venter is a co-founder, executive chairman and CEO of Human Longevity Inc, a privately held genomics, and cell therapy-based diagnostic, and therapeutic company focused on extending the healthy, high performance human life span. He is also founder, executive chairman, and CEO of the J. Craig Venter Institute, and a co-founder, executive chairman, and co-chief scientist of Synthetic Genomics Inc., a privately held company focused on developing products, and solutions using synthetic genomic technologies.
Dr. Venter is renowned for his contributions in sequencing the first draft human genome in 2001, the first complete diploid human genome in 2007, and construction of the first synthetic bacterial cell in 2010.
Currently, he and his teams are focused on a variety of projects, and programs including: synthetic genomic research, and the application of these advances to develop new vaccines, and food and nutritional products, new biofuels, and biochemicals; continued analysis of the human genome including the human microbiome, and discovering, and understanding genetic diversity in the world's oceans.
Dr. Venter is a recipient of the 2008 National Medal of Science, and is a member of the National Academy of Sciences.
He is the author of Life at the Speed of Light: From the Double Helix to the Dawn of Digital Life (Viking, 2013), and A Life Decoded: My Genome: My Life (Viking, 2007).
Liewei Wang, M.D., Ph.D.
Professor of the Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
Dr. Liewei Wang is a Professor of the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic. She received her M.D. from FuDan University, Shanghai, China, and a PhD., with an emphasis on cancer biology, and cancer pharmacology, from the Mayo Graduate School.
Dr. Wang has developed a research program with a focus on the use of high throughput genomic technology including array based and next generation sequencing methods, joined with a cell-based model system that consists of 300 lymphoblastoid cell lines, to study mechanisms of cancer biology, and antineoplastic drug resistance, both chemotherapy and radiation therapy.
In addition to her career-long involvement in pharmacogenomics, Dr. Wang has extensive experience in functional genomics. She is involved in many clinical translational studies which help identify, and understand biomarkers associated with clinical response to endocrine therapy, and chemotherapy in breast cancer patients.
Dr. Wang is a member of several key programs at Mayo including: the Mayo-NIH Comprehensive Cancer Center, and the Mayo Center for Individualized Medicine. She is also Co-Principal Investigator, and the leader of the Functional Genomics Group for the Mayo-NIH Pharmacogenetics Research Network, and the Associate Director for the Pharmacogenomics Program in the Mayo CIM.
Tonya Ward, Ph.D.
Postdoctoral Scholar, Knights Lab, University of Minnesota
Dr. Tonya Ward is a postdoctoral scholar in the Knights Lab at the University of Minnesota.
Dr. Ward received a B.S., Honors Specialization in Genetics, from the University of Western Ontario where she studied the effects of environmental toxins on mammalian genomic mutation frequencies. She received a Ph.D. in Biochemistry from the University of Ottawa where she studied immune components of human milk including the human milk microbiome and bioactive milk proteins.
Her current work focuses on the dynamics of the microbiome in relation to antibiotic usage, and allergy development.
Richard Weinshilboum, M.D.
Professor of Medicine and Pharmacology, Mayo Clinic College of Medicine
Dr. Richard Weinshilboum is a Professor of Medicine and Pharmacology at Mayo Clinic College of Medicine, and the Mary Lou and John H. Dasburg Professor of Cancer Genomics. He received an M.D. from University of Kansas School of Medicine, completed residency training in internal medicine at Massachusetts General Hospital, and completed a postdoctoral research fellowship at the National Institutes of Health in the laboratory of Nobel laureate Julius Axelrod.
Dr. Weinshilboum’s research focusing on pharmacogenetics and pharmacogenomics, has resulted in the discovery, and characterization of a series of clinically important genetic polymorphisms (variations in DNA sequence involved in drug, neurotransmitter and hormone metabolism), the functional characterization of these common genetic polymorphisms, and the rapid translation of that information into clinical studies designed to test hypotheses with regard to individual variation in drug response or disease pathophysiology. This research has made it possible to develop molecular tests that help protect patients from life-threatening, genetically mediated adverse drug reactions.
He has chaired the Pharmacogenomics Research Network, a National Institutes of Health-funded initiative that includes scientists from Mayo Clinic, Harvard University, and Stanford University, among others. He is a past member of the advisory councils for the National Institute of General Medical Sciences and the National Human Genome Research Institute, the sponsor of the Human Genome Project.
Dr. Weinshilboum is recognized as an internationally renowned medical investigator, with more than 400 peer-reviewed articles, and chapters. His numerous awards include the Mayo Distinguished Investigator and Distinguished Educator awards.
David Weinstock, M.D.
Associate Professor Medicine, Dana-Farber Cancer Institute and Harvard Medical School
Dr. David Weinstock is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and director of the Dana-Farber hematologic malignancies patient-derived xenograft effort.
Dr. Weinstock’s clinical expertise is in the care of patients undergoing hematopoietic cell transplantation. His laboratory investigates the pathogenesis, and targeting of lymphoid malignancies.
Kristin Weitzel, PharmD
Clinical Associate Professor and Associate Director, Personalized Medicine Program, University of Florida
Dr. Kristin Weitzel is currently Associate Director of the University of Florida Health (UF Health) Personalized Medicine Program and Associate Chair and Associate Professor in the Department of Pharmacotherapy and Translational Research in the College of Pharmacy. Kristin Weitzel received her Doctor of Pharmacy from the University of Florida and completed residency training at Virginia Commonwealth University/Medical College of Virginia.
She has practice, and leadership experience in pharmacogenomics, primary care, drug information, and experiential education. Dr. Weitzel currently leads patient, student, and health care professional education efforts supporting clinical implementation of pharmacogenomics within the UF Health Personalized Medicine Program, and serves as Residency Program Co-Director for the Pharmacogenetics residency.
Dr. Weitzel is an Entrepreneurship Faculty Fellow in the Warrington College of Business Center for Entrepreneurship and Innovation, a Fellow of the American Pharmacists Association, and is a past recipient of the College of Pharmacy Teacher of the Year Award, and the American Pharmacists Association Distinguished Achievement in Service Award.
Derek Wildman, Ph.D.
Clinical Associate Professor and Associate Director, Personalized Medicine Program, University of Florida
Dr. Derek Wildman is a Professor of Molecular and Integrative Physiology in The School of Molecular and Cellular Biology, and a faculty member at the Carl R. Woese Institute for Genomic Biology at the University of Illinois at Urbana-Champaign. Prior to this position, Dr. Wildman worked in the Center for Molecular Medicine and Genetics at Wayne State University. He received his Ph.D. from New York University.
Dr. Wildman’s research uses molecular evolutionary, and comparative genomic approaches to study the genomics of pregnancy, and obstetric syndromes. His laboratory uses high-throughput computational methods, Next-Generation Sequencing, quantitative PCR, and epigenomics to explore gene expression patterns involved in human pregnancy, and the brain.
He is the current Editor-in-Chief of Molecular Phylogenetics and Evolution.
Jieping Ye, Ph.D.
Associate Professor, University of Michigan
Jieping Ye is an Associate Professor of Department of Computational Medicine and Bioinformatics and Department of Electrical Engineering and Computer Science at the University of Michigan. He received his Ph.D. degree in Computer Science from the University of Minnesota.
His research interests include machine learning, data mining, and biomedical informatics.
Dr. Ye serves as a PC Co-Chair of SDM 2015 in addition to an Action/Associate Editor of Data Mining and Knowledge Discovery, IEEE Transactions on Knowledge and Data Engineering, and IEEE Transactions on Pattern Analysis and Machine Intelligence. He has served as Senior Program Committee/Area Chair/Program Committee Vice Chair of the NIPS, ICML, KDD, IJCAI, ICDM, SDM, ACML, and PAKDD conferences.
Dr. Ye received the NSF CAREER Award in 2010. His papers have been selected for the outstanding student paper at ICML in 2004, the KDD best research paper honorable mention in 2010, the KDD best research paper nomination in 2011, and 2012, the SDM best research paper runner up in 2013, the KDD best research paper runner up in 2013, and the KDD best student paper award in 2014.